Single	O
dose	O
intranasal	O
administration	O
of	O
retinal	B-protein
autoantigen	I-protein
generates	O
a	O
rapid	O
accumulation	O
and	O
cell	O
activation	O
in	O
draining	O
lymph	O
node	O
and	O
spleen	O
:	O
implications	O
for	O
tolerance	O
therapy	O
.	O

BACKGROUND/AIMS	O
:	O
A	O
single	O
intranasal	O
delivery	O
of	O
retinal	B-protein
autoantigen	I-protein
suppresses	O
effectively	O
experimental	O
autoimmune	O
uveoretinitis	O
(	O
EAU	O
)	O
.	O

To	O
further	O
unravel	O
underlying	O
mechanisms	O
the	O
authors	O
wished	O
to	O
determine	O
,	O
firstly	O
,	O
the	O
kinetics	O
of	O
antigen	O
delivery	O
and	O
,	O
secondly	O
,	O
the	O
early	O
cellular	O
responses	O
involved	O
in	O
the	O
initial	O
stages	O
of	O
nasal	O
mucosal	O
tolerance	O
induction	O
.	O

METHODS	O
:	O
Flow	O
cytometry	O
,	O
cell	O
proliferation	O
assays	O
,	O
and	O
microscopy	O
were	O
used	O
to	O
track	O
antigen	B-protein
following	O
a	O
single	O
,	O
intranasal	O
dose	O
of	O
Alexa-488	B-protein
labelled	I-protein
retinal	I-protein
antigen	I-protein
.	O

RESULTS	O
:	O
A	O
rapid	O
accumulation	O
of	O
antigen	B-protein
within	O
both	O
superficial	O
cervical	O
lymph	O
nodes	O
(	O
SCLN	O
)	O
and	O
spleen	O
was	O
observed	O
after	O
30	O
minutes	O
.	O

Significant	O
proliferative	O
responses	O
to	O
IRBP	O
were	O
elicited	O
by	O
48	O
hours	O
indicating	O
that	O
systemic	O
priming	O
of	O
naive	B-cell_type
T	I-cell_type
cells	I-cell_type
to	O
retinal	B-protein
antigen	I-protein
had	O
occurred	O
.	O

Cell	O
activation	O
was	O
further	O
confirmed	O
by	O
immunoprecipitation	O
studies	O
,	O
which	O
demonstrated	O
phosphorylation	O
of	O
STAT4	B-protein
but	O
not	O
STAT6	B-protein
in	O
both	O
lymph	O
nodes	O
and	O
spleen	O
.	O

However	O
,	O
at	O
24	O
hours	O
,	O
STAT4	O
heterodimerisation	O
with	O
STAT	B-protein
3	I-protein
was	O
only	O
observed	O
in	O
spleen	O
.	O

CONCLUSIONS	O
:	O
The	O
results	O
provide	O
novel	O
evidence	O
that	O
following	O
a	O
single	O
intranasal	O
application	O
rapid	O
transfer	O
of	O
antigen	B-protein
occurs	O
.	O

Resulting	O
T	O
cell	O
proliferation	O
develops	O
consequent	O
to	O
differential	O
cell	O
signalling	O
in	O
SCLN	O
and	O
spleen	O
.	O

Further	O
understanding	O
of	O
these	O
underlying	O
cellular	O
mechanisms	O
,	O
in	O
particular	O
as	O
is	O
inferred	O
by	O
the	O
results	O
the	O
contribution	O
of	O
local	O
versus	O
systemic	O
tolerance	O
induction	O
,	O
may	O
assist	O
in	O
strategies	O
to	O
clinically	O
apply	O
mucosal	O
tolerance	O
therapy	O
successfully	O
.	O

Br	NULL
J	NULL
Ophthalmol	NULL
2001	NULL
;	NULL
85:1001-1006	NULL
Division	NULL
of	NULL
Ophthalmology	NULL
,	NULL
University	NULL
of	NULL
Aberdeen	NULL
,	NULL
UK	NULL
A	NULL
D	NULL
Dick	NULL
V	NULL
Sharma	NULL
]	NULL
Liversidge	NULL
Department	NULL
of	NULL
Ophthalmology	NULL
,	NULL
University	NULL
of	NULL
Bristol	NULL
,	NULL
UK	NULL
A	NULL
D	NULL
Dick	NULL
Correspondence	NULL
to	NULL
:	NULL
Professor	NULL
Andrew	NULL
D	NULL
Dick	NULL
,	NULL
Division	NULL
of	NULL
Ophthalmology	NULL
,	NULL
Bristol	NULL
Eye	NULL
Hospital	NULL
,	NULL
Lower	NULL
Maudlin	NULL
Street	NULL
,	NULL
Bristol	NULL
BSI	NULL
2LX	NULL
,	NULL
UK	NULL
a.dick	NULL
@	NULL
bristol.ac.uk	NULL
Accepted	NULL
for	NULL
publication	NULL
2	NULL
April	NULL
2001	NULL
1001	NULL
Single	NULL
dose	NULL
intranasal	NULL
administration	NULL
of	NULL
retinal	NULL
autoantigen	NULL
generates	NULL
a	NULL
rapid	NULL
accumulation	NULL
and	NULL
cell	NULL
activation	NULL
in	NULL
draining	NULL
lymph	NULL
node	NULL
and	NULL
spleen	NULL
:	NULL
implications	NULL
for	NULL
tolerance	NULL
therapy	NULL
Andrew	NULL
D	NULL
Dick	NULL
,	NULL
Vijay	NULL
Sharma	NULL
,	NULL
Janet	NULL
Liversidge	NULL
Abstract	NULL
Backgroundlaims-A	NULL
single	NULL
intranasal	NULL
delivery	NULL
of	NULL
retinal	NULL
autoantigen	NULL
suppresses	NULL
effectively	NULL
-	NULL
experimental	NULL
-	NULL
autoimmune	NULL
uveoretinitis	NULL
(	NULL
EAU	NULL
)	NULL
.	NULL

To	NULL
further	NULL
unravel	NULL
underlying	NULL
mechanisms	NULL
the	NULL
authors	NULL
wished	NULL
to	NULL
determine	NULL
,	NULL
firstly	NULL
,	NULL
the	NULL
kinetics	NULL
of	NULL
antigen	NULL
delivery	NULL
and	NULL
,	NULL
secondly	NULL
,	NULL
the	NULL
early	NULL
cellular	NULL
responses	NULL
involved	NULL
in	NULL
the	NULL
initial	NULL
stages	NULL
of	NULL
nasal	NULL
mucosal	NULL
tolerance	NULL
induction	NULL
.	NULL

Methods-Flow	NULL
cytometry	NULL
,	NULL
cell	NULL
proliferation	NULL
assays	NULL
,	NULL
and	NULL
microscopy	NULL
were	NULL
used	NULL
to	NULL
track	NULL
antigen	NULL
following	NULL
a	NULL
single	NULL
,	NULL
intranasal	NULL
dose	NULL
of	NULL
Alexa-488	NULL
labelled	NULL
retinal	NULL
antigen	NULL
.	NULL

Results-A	NULL
rapid	NULL
accumulation	NULL
of	NULL
antigen	NULL
within	NULL
both	NULL
superficial	NULL
cervical	NULL
lymph	NULL
nodes	NULL
(	NULL
SCLN	NULL
)	NULL
and	NULL
spleen	NULL
was	NULL
observed	NULL
after	NULL
30	NULL
minutes	NULL
.	NULL

Significant	NULL
proliferative	NULL
responses	NULL
to	NULL
IRBP	NULL
were	NULL
elicited	NULL
by	NULL
48	NULL
hours	NULL
indicating	NULL
that	NULL
systemic	NULL
priming	NULL
of	NULL
naive	NULL
T	NULL
cells	NULL
to	NULL
retinal	NULL
antigen	NULL
had	NULL
occurred	NULL
.	NULL

Cell	NULL
activation	NULL
was	NULL
further	NULL
confirmed	NULL
by	NULL
immunoprecipitation	NULL
studies	NULL
,	NULL
which	NULL
demonstrated	NULL
phosphorylation	NULL
of	NULL
STAT4	NULL
but	NULL
not	NULL
STAT6	NULL
in	NULL
both	NULL
lymph	NULL
nodes	NULL
and	NULL
spleen	NULL
.	NULL

However	NULL
,	NULL
at	NULL
24	NULL
hours	NULL
,	NULL
STAT4	NULL
heterodimerisation	NULL
with	NULL
STAT	NULL
3	NULL
was	NULL
only	NULL
observed	NULL
in	NULL
spleen	NULL
.	NULL

Conclusions-The	NULL
results	NULL
provide	NULL
novel	NULL
evidence	NULL
that	NULL
following	NULL
a	NULL
single	NULL
intranasal	NULL
application	NULL
rapid	NULL
transfer	NULL
of	NULL
antigen	NULL
oc-curs	NULL
.	NULL

Resulting	NULL
T	NULL
cell	NULL
proliferation	NULL
develops	NULL
-	NULL
consequent	NULL
-	NULL
to	NULL
-	NULL
differential	NULL
cell	NULL
signalling	NULL
in	NULL
SCLN	NULL
and	NULL
spleen	NULL
.	NULL

Further	NULL
understanding	NULL
of	NULL
these	NULL
underlying	NULL
cellular	NULL
mechanisms	NULL
,	NULL
in	NULL
particular	NULL
as	NULL
is	NULL
inferred	NULL
by	NULL
the	NULL
results	NULL
the	NULL
contribution	NULL
of	NULL
local	NULL
versus	NULL
systemic	NULL
tolerance	NULL
induction	NULL
,	NULL
may	NULL
assist	NULL
in	NULL
strategies	NULL
to	NULL
clinically	NULL
apply	NULL
mucosal	NULL
tolerance	NULL
therapy	NULL
successfully	NULL
.	NULL

(	NULL
Br	NULL
J	NULL
Ophthalmol	NULL
2001	NULL
;	NULL
85:1001-1006	NULL
)	NULL
Models	NULL
of	NULL
tolerance	NULL
induction	NULL
via	NULL
the	NULL
mucosa	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
effective	NULL
for	NULL
the	NULL
prevention	NULL
of	NULL
several	NULL
autoimmune	NULL
diseases	NULL
.	NULL

The	NULL
effectiveness	NULL
of	NULL
the	NULL
treatment	NULL
is	NULL
dependent	NULL
on	NULL
parameters	NULL
such	NULL
as	NULL
the	NULL
antigen	NULL
used	NULL
,	NULL
its	NULL
dose	NULL
and	NULL
route	NULL
of	NULL
delivery	NULL
,	NULL
and	NULL
various	NULL
mechanisms	NULL
have	NULL
been	NULL
identified	NULL
,	NULL
including	NULL
T	NULL
cell	NULL
anergy	NULL
,	NULL
generation	NULL
of	NULL
regulatory	NULL
Th3	NULL
(	NULL
TGFB	NULL
producing	NULL
)	NULL
cells	NULL
or	NULL
CD8+	NULL
T	NULL
cells	NULL
and	NULL
y8	NULL
T	NULL
cells	NULL
.	NULL
``	NULL

Models	NULL
used	NULL
include	NULL
experimental	NULL
autoimmune	NULL
uveoretinitis	NULL
(	NULL
EAU	NULL
)	NULL
,	NULL
an	NULL
organ	NULL
specific	NULL
CD4+	NULL
T	NULL
cell	NULL
mediated	NULL
ocular	NULL
inflammation	NULL
www	NULL
.	NULL

bjophthalmol	NULL
.	NULL

com	NULL
resulting	NULL
in	NULL
destruction	NULL
of	NULL
photoreceptors	NULL
that	NULL
clinicopathologically	NULL
closely	NULL
resembles	NULL
uveitis	NULL
in	NULL
humans	NULL
.	NULL
'	NULL

Antigen	NULL
specific	NULL
suppression	NULL
of	NULL
EAU	NULL
is	NULL
obtained	NULL
consistently	NULL
when	NULL
retinal	NULL
autoantigen	NULL
is	NULL
delivered	NULL
before	NULL
immunisation	NULL
via	NULL
a	NULL
variety	NULL
of	NULL
mucosal	NULL
surfaces	NULL
'	NULL
``	NULL
and	NULL
with	NULL
appropriate	NULL
immunosuppression	NULL
,	NULL
some	NULL
protective	NULL
immunity	NULL
can	NULL
be	NULL
also	NULL
be	NULL
induced	NULL
in	NULL
primed	NULL
animals	NULL
.	NULL
``	NULL

''	NULL
However	NULL
,	NULL
clinical	NULL
trials	NULL
in	NULL
multiple	NULL
sclerosis	NULL
,	NULL
rheumatoid	NULL
arthritis	NULL
,	NULL
and	NULL
uveitis	NULL
have	NULL
underlined	NULL
the	NULL
need	NULL
to	NULL
fully	NULL
define	NULL
the	NULL
parameters	NULL
involved	NULL
in	NULL
mucosal	NULL
tolerance	NULL
to	NULL
avoid	NULL
worsening	NULL
ongoing	NULL
autoimmune	NULL
disease	NULL
.	NULL
``	NULL

'	NULL
Recent	NULL
research	NULL
has	NULL
focused	NULL
on	NULL
the	NULL
antigen	NULL
used	NULL
and	NULL
its	NULL
presentation	NULL
to	NULL
the	NULL
immune	NULL
system	NULL
,	NULL
including	NULL
both	NULL
peptide	NULL
affinity	NULL
for	NULL
MHC	NULL
class	NULL
II	NULL
binding	NULL
``	NULL
as	NULL
well	NULL
as	NULL
inherent	NULL
hierarchical	NULL
ability	NULL
of	NULL
T	NULL
cell	NULL
epitopes	NULL
to	NULL
induce	NULL
tolerance	NULL
.	NULL
``	NULL

Together	NULL
with	NULL
data	NULL
on	NULL
the	NULL
dosage	NULL
and	NULL
timing	NULL
of	NULL
treatment	NULL
,	NULL
these	NULL
important	NULL
observations	NULL
indicate	NULL
that	NULL
routes	NULL
of	NULL
administration	NULL
such	NULL
as	NULL
nasal	NULL
delivery	NULL
and	NULL
intravenous	NULL
injection	NULL
``	NULL
that	NULL
avoid	NULL
proteolytic	NULL
degradation	NULL
and	NULL
therefore	NULL
deliver	NULL
tolerogenic	NULL
doses	NULL
of	NULL
antigen	NULL
accurately	NULL
will	NULL
be	NULL
important	NULL
therapeuti-cally	NULL
.	NULL

With	NULL
respect	NULL
to	NULL
nasal	NULL
tolerance	NULL
induction	NULL
,	NULL
evidence	NULL
in	NULL
support	NULL
of	NULL
intranasal	NULL
antigen	NULL
administration	NULL
regulating	NULL
CD4+	NULL
T	NULL
cell	NULL
function	NULL
is	NULL
accumulating	NULL
.	NULL

Recent	NULL
data	NULL
in	NULL
allergy	NULL
,	NULL
and	NULL
autoimmune	NULL
models	NULL
including	NULL
EAU	NULL
,	NULL
have	NULL
shown	NULL
that	NULL
mucosal	NULL
administration	NULL
of	NULL
autoantigen	NULL
results	NULL
in	NULL
early	NULL
activation	NULL
followed	NULL
by	NULL
apoptosis	NULL
of	NULL
T	NULL
cell	NULL
populations	NULL
and	NULL
invoke	NULL
a	NULL
role	NULL
for	NULL
IL-10	NULL
in	NULL
the	NULL
generation	NULL
of	NULL
immunological	NULL
non-responsiveness	NULL
.	NULL
'	NULL

''	NULL
'*	NULL
'	NULL
``	NULL
Notably	NULL
,	NULL
in	NULL
the	NULL
EAU	NULL
model	NULL
,	NULL
we	NULL
demonstrated	NULL
that	NULL
although	NULL
regulatory	NULL
cells	NULL
were	NULL
generated	NULL
,	NULL
tolerance	NULL
could	NULL
only	NULL
be	NULL
transferred	NULL
from	NULL
spleen	NULL
,	NULL
and	NULL
cells	NULL
that	NULL
did	NULL
infiltrate	NULL
the	NULL
retina	NULL
in	NULL
treated	NULL
animals	NULL
produced	NULL
IL-10	NULL
.	NULL
``	NULL

The	NULL
data	NULL
imply	NULL
an	NULL
important	NULL
role	NULL
for	NULL
antigen	NULL
presenting	NULL
cells	NULL
in	NULL
the	NULL
process	NULL
,	NULL
and	NULL
a	NULL
pivotal	NULL
role	NULL
for	NULL
the	NULL
regional	NULL
drainage	NULL
lymph	NULL
nodes	NULL
in	NULL
the	NULL
induction	NULL
of	NULL
tolerance	NULL
has	NULL
been	NULL
shown	NULL
.	NULL
``	NULL

However	NULL
,	NULL
the	NULL
cellular	NULL
mechanisms	NULL
involved	NULL
remain	NULL
unde-fined	NULL
.	NULL

If	NULL
antigen	NULL
specific	NULL
T	NULL
cell	NULL
activation	NULL
and	NULL
proliferation	NULL
is	NULL
an	NULL
essential	NULL
first	NULL
step	NULL
in	NULL
the	NULL
process	NULL
,	NULL
then	NULL
presentation	NULL
of	NULL
antigen	NULL
on	NULL
functionally	NULL
mature	NULL
dendritic	NULL
cells	NULL
(	NULL
DC	NULL
)	NULL
must	NULL
be	NULL
involved	NULL
.	NULL
``	NULL

The	NULL
respiratory	NULL
tract	NULL
contains	NULL
a	NULL
contiguous	NULL
network	NULL
of	NULL
dendritic	NULL
cells	NULL
(	NULL
RTDC	NULL
)	NULL
that	NULL
have	NULL
a	NULL
rapid	NULL
turnover	NULL
particularly	NULL
in	NULL
response	NULL
to	NULL
local	NULL
inflammatory	NULL
stimuli	NULL
.	NULL
``	NULL

*	NULL
In	NULL
both	NULL
rats	NULL
and	NULL
mice	NULL
data	NULL
have	NULL
shown	NULL
that	NULL
freshly	NULL
isolated	NULL
RTDC	NULL
1002	NULL
are	NULL
functionally	NULL
immature	NULL
and	NULL
following	NULL
an	NULL
OVA	NULL
pulse	NULL
are	NULL
capable	NULL
of	NULL
presenting	NULL
antigen	NULL
to	NULL
naive	NULL
T	NULL
cells	NULL
.	NULL
``	NULL

*	NULL
Functional	NULL
immaturity	NULL
in	NULL
DC	NULL
is	NULL
linked	NULL
to	NULL
their	NULL
capacity	NULL
to	NULL
induce	NULL
peripheral	NULL
tolerance	NULL
rather	NULL
than	NULL
immunity	NULL
``	NULL
*	NULL
;	NULL
however	NULL
,	NULL
the	NULL
ability	NULL
of	NULL
RTDC	NULL
to	NULL
provide	NULL
a	NULL
``	NULL
default	NULL
``	NULL
tolerogenic	NULL
response	NULL
in	NULL
vivo	NULL
may	NULL
also	NULL
rely	NULL
on	NULL
the	NULL
microenvironment	NULL
provided	NULL
by	NULL
the	NULL
cervical	NULL
regional	NULL
drainage	NULL
lymph	NULL
nodes	NULL
.	NULL
``	NULL

Soluble	NULL
antigen	NULL
not	NULL
processed	NULL
by	NULL
RTDC	NULL
but	NULL
entering	NULL
the	NULL
lymphatics	NULL
and	NULL
blood	NULL
stream	NULL
may	NULL
also	NULL
be	NULL
important	NULL
as	NULL
systemic	NULL
presentation	NULL
of	NULL
soluble	NULL
antigen	NULL
(	NULL
involving	NULL
both	NULL
lymph	NULL
nodes	NULL
and	NULL
spleen	NULL
)	NULL
,	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
inflammatory	NULL
stimuli	NULL
,	NULL
has	NULL
also	NULL
been	NULL
linked	NULL
to	NULL
the	NULL
induction	NULL
of	NULL
peripheral	NULL
tolerance	NULL
(	NULL
reviewed	NULL
by	NULL
Liblau	NULL
et	NULL
al	NULL
'	NULL
``	NULL
)	NULL
.	NULL

Tolerance	NULL
induction	NULL
is	NULL
rapid	NULL
,	NULL
as	NULL
we	NULL
have	NULL
recently	NULL
shown	NULL
following	NULL
a	NULL
single	NULL
intranasal	NULL
dose	NULL
of	NULL
retinal	NULL
antigen	NULL
,	NULL
which	NULL
suppressed	NULL
EAU	NULL
.	NULL
``	NULL

In	NULL
this	NULL
preliminary	NULL
study	NULL
,	NULL
therefore	NULL
,	NULL
we	NULL
wished	NULL
to	NULL
document	NULL
the	NULL
early	NULL
events	NULL
during	NULL
induction	NULL
of	NULL
nasal	NULL
mucosal	NULL
tolerance	NULL
induction	NULL
by	NULL
observing	NULL
,	NULL
firstly	NULL
,	NULL
the	NULL
kinetics	NULL
of	NULL
antigen	NULL
distribution	NULL
to	NULL
superficial	NULL
cervical	NULL
lymph	NULL
nodes	NULL
(	NULL
SCLN	NULL
)	NULL
and	NULL
spleen	NULL
and	NULL
,	NULL
secondly	NULL
,	NULL
cellular	NULL
activation	NULL
via	NULL
cell	NULL
proliferation	NULL
and	NULL
immunohistochemistry	NULL
of	NULL
signalling	NULL
proteins-for	NULL
example	NULL
,	NULL
signal	NULL
transducer	NULL
and	NULL
activator	NULL
of	NULL
transcription	NULL
(	NULL
STAT	NULL
)	NULL
expression	NULL
.	NULL

Methods	NULL
ANIMALS	NULL
,	NULL
ANTIGEN	NULL
,	NULL
AND	NULL
ANTIGEN	NULL
ADMINISTRATION	NULL
Adult	NULL
female	NULL
Lewis	NULL
rats	NULL
(	NULL
Charles	NULL
Rivers	NULL
,	NULL
UK	NULL
)	NULL
,	NULL
6-9	NULL
week	NULL
old	NULL
,	NULL
were	NULL
housed	NULL
in	NULL
the	NULL
Biological	NULL
Services	NULL
Unit	NULL
,	NULL
University	NULL
of	NULL
Aberdeen	NULL
under	NULL
non-specific	NULL
pathogen-free	NULL
conditions	NULL
.	NULL

Animals	NULL
used	NULL
in	NULL
all	NULL
experiments	NULL
were	NULL
treated	NULL
according	NULL
to	NULL
the	NULL
ARVO	NULL
statement	NULL
for	NULL
the	NULL
use	NULL
of	NULL
animals	NULL
in	NULL
ophthalmic	NULL
and	NULL
vision	NULL
research	NULL
.	NULL

S-antigen	NULL
(	NULL
S-Ag	NULL
)	NULL
,	NULL
interphotoreceptor	NULL
retinoid	NULL
binding	NULL
protein	NULL
(	NULL
IRBP	NULL
)	NULL
,	NULL
or	NULL
retinal	NULL
extract	NULL
(	NULL
RE	NULL
;	NULL
containing	NULL
a	NULL
mixture	NULL
of	NULL
these	NULL
and	NULL
other	NULL
soluble	NULL
uveitogenic	NULL
antigens	NULL
)	NULL
induce	NULL
tolerance	NULL
to	NULL
S-Ag	NULL
,	NULL
IRBP	NULL
,	NULL
or	NULL
RE	NULL
induced	NULL
EAU	NULL
.	NULL
``	NULL

°	NULL
*	NULL
RE	NULL
was	NULL
prepared	NULL
as	NULL
described	NULL
``	NULL
by	NULL
hypotonic	NULL
lysis	NULL
of	NULL
freshly	NULL
dissected	NULL
bovine	NULL
retinas	NULL
in	NULL
the	NULL
dark	NULL
.	NULL

S-Ag	NULL
and	NULL
IRBP	NULL
were	NULL
purified	NULL
from	NULL
retinal	NULL
extract	NULL
under	NULL
aseptic	NULL
conditions	NULL
and	NULL
filter	NULL
sterilised	NULL
as	NULL
previously	NULL
described	NULL
.	NULL
``	NULL

For	NULL
kinetic	NULL
experiments	NULL
,	NULL
antigen	NULL
(	NULL
maximum	NULL
of	NULL
2	NULL
mg/m	NULL
!	NULL
)	NULL

was	NULL
fluorescently	NULL
labelled	NULL
with	NULL
Alexa-488	NULL
labelling	NULL
kit	NULL
(	NULL
Molecular	NULL
Probes	NULL
Inc	NULL
,	NULL
Leiden	NULL
,	NULL
Netherlands	NULL
)	NULL
,	NULL
following	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
.	NULL

Free	NULL
excess	NULL
dye	NULL
was	NULL
removed	NULL
with	NULL
extensive	NULL
dialysis	NULL
against	NULL
phosphate	NULL
buffered	NULL
saline	NULL
(	NULL
PBS	NULL
)	NULL
.	NULL

Labelled	NULL
antigen	NULL
was	NULL
detected	NULL
on	NULL
western	NULL
blots	NULL
with	NULL
rabbit	NULL
polyclonal	NULL
anti-Alexa-488	NULL
antibody	NULL
(	NULL
Molecular	NULL
Probes	NULL
Inc	NULL
)	NULL
and	NULL
was	NULL
functional	NULL
in	NULL
proliferation	NULL
assays	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Single	NULL
doses	NULL
of	NULL
intranasal	NULL
antigen	NULL
in	NULL
PBS	NULL
(	NULL
30	NULL
ul	NULL
;	NULL
either	NULL
total	NULL
S-Ag	NULL
dose	NULL
of	NULL
60	NULL
ug	NULL
or	NULL
RE	NULL
dose	NULL
of	NULL
150	NULL
ug	NULL
)	NULL
or	NULL
PBS	NULL
alone	NULL
as	NULL
control	NULL
were	NULL
administered	NULL
directly	NULL
via	NULL
an	NULL
Oxford	NULL
pipette	NULL
.	NULL

T	NULL
CELL	NULL
PROLIFERATION	NULL
ASSAY	NULL
Proliferation	NULL
assays	NULL
were	NULL
performed	NULL
on	NULL
both	NULL
lymph	NULL
node	NULL
and	NULL
spleen	NULL
preparations	NULL
following	NULL
intranasal	NULL
administration	NULL
of	NULL
antigen	NULL
.	NULL

Cells	NULL
were	NULL
www	NULL
.	NULL

bjophthalmol	NULL
.	NULL

com	NULL
Dick	NULL
,	NULL
Sharma	NULL
,	NULL
Liversidge	NULL
seeded	NULL
in	NULL
quadruplicate	NULL
at	NULL
2	NULL
x	NULL
10	NULL
``	NULL
/well	NULL
into	NULL
round	NULL
bottomed	NULL
96	NULL
well	NULL
plates	NULL
in	NULL
either	NULL
compete	NULL
media	NULL
alone	NULL
,	NULL
media	NULL
containing	NULL
20	NULL
ug/ml	NULL
IRBP	NULL
,	NULL
or	NULL
control	NULL
stimulation	NULL
with	NULL
PPD	NULL
(	NULL
20	NULL
ug/ml	NULL
)	NULL
or	NULL
Con	NULL
A	NULL
(	NULL
2.5	NULL
ug/ml	NULL
)	NULL
.	NULL

After	NULL
72	NULL
hours	NULL
of	NULL
incubation	NULL
at	NULL
37°C	NULL
,	NULL
5	NULL
%	NULL
carbon	NULL
dioxide	NULL
cells	NULL
were	NULL
pulsed	NULL
with	NULL
0.5	NULL
uCi	NULL
of	NULL
3	NULL
[	NULL
H	NULL
]	NULL
-thymidine	NULL
for	NULL
a	NULL
further	NULL
16	NULL
hours	NULL
.	NULL

Plates	NULL
were	NULL
then	NULL
harvested	NULL
and	NULL
counts/min	NULL
(	NULL
CPM	NULL
)	NULL
recorded	NULL
as	NULL
mean	NULL
(	NULL
SD	NULL
)	NULL
(	NULL
Packard	NULL
matrix	NULL
system	NULL
)	NULL
.	NULL

Stimulation	NULL
index	NULL
(	NULL
mean	NULL
CPM	NULL
of	NULL
quadruplicate	NULL
cultures	NULL
with	NULL
stimulant	NULL
divided	NULL
by	NULL
mean	NULL
CPM	NULL
of	NULL
quadruplicate	NULL
control	NULL
cultures	NULL
)	NULL
was	NULL
used	NULL
to	NULL
present	NULL
proliferation	NULL
data	NULL
,	NULL
as	NULL
experiments	NULL
were	NULL
carried	NULL
out	NULL
on	NULL
separate	NULL
days	NULL
.	NULL

MICROSCOPIC	NULL
EXAMINATION	NULL
OF	NULL
CELLS	NULL
AND	NULL
TISSUE	NULL
AND	NULL
IMMUNOHISTOCHEMISTRY	NULL
Lymph	NULL
nodes	NULL
and	NULL
spleen	NULL
were	NULL
dissected	NULL
at	NULL
given	NULL
time	NULL
points	NULL
after	NULL
intranasal	NULL
administration	NULL
of	NULL
retinal	NULL
antigen	NULL
.	NULL

Tissue	NULL
was	NULL
analysed	NULL
for	NULL
detection	NULL
of	NULL
(	NULL
a	NULL
)	NULL
Alexa-488	NULL
labelled	NULL
antigen	NULL
by	NULL
scanning	NULL
laser	NULL
confocal	NULL
microscopy	NULL
(	NULL
Bio-Rad	NULL
MRC	NULL
1024	NULL
)	NULL
,	NULL
and	NULL
(	NULL
b	NULL
)	NULL
STAT	NULL
4	NULL
and	NULL
STAT	NULL
6	NULL
by	NULL
immunohistochemistry	NULL
(	NULL
alkaline	NULL
phosphatase	NULL
antialkaline	NULL
phosphatase	NULL
;	NULL
APAAP	NULL
)	NULL
.	NULL

Fresh	NULL
frozen	NULL
tissue	NULL
in	NULL
OCT	NULL
was	NULL
used	NULL
for	NULL
sectioning	NULL
.	NULL

Serial	NULL
5-10	NULL
um	NULL
sections	NULL
were	NULL
cut	NULL
,	NULL
air	NULL
dried	NULL
and	NULL
,	NULL
for	NULL
STAT	NULL
immunostaining	NULL
,	NULL
fixed	NULL
in	NULL
100	NULL
%	NULL
ice	NULL
cold	NULL
acetone	NULL
.	NULL

Following	NULL
rehydration	NULL
in	NULL
TRIS	NULL
buffered	NULL
saline	NULL
(	NULL
TBS	NULL
)	NULL
,	NULL
sections	NULL
were	NULL
blocked	NULL
with	NULL
TBS/1	NULL
%	NULL
normal	NULL
rabbit	NULL
serum	NULL
and	NULL
then	NULL
avidin	NULL
D	NULL
block	NULL
solution	NULL
(	NULL
Vector	NULL
Laboratories	NULL
,	NULL
USA	NULL
)	NULL
.	NULL

STAT	NULL
staining	NULL
was	NULL
performed	NULL
using	NULL
rabbit	NULL
polyclonal	NULL
antibodies	NULL
(	NULL
STAT4	NULL
,	NULL
C20	NULL
;	NULL
STAT6	NULL
,	NULL
M20	NULL
,	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
,	NULL
CA	NULL
,	NULL
USA	NULL
)	NULL
using	NULL
appropriate	NULL
blocking	NULL
peptides	NULL
as	NULL
negative	NULL
control	NULL
and	NULL
detected	NULL
with	NULL
rat	NULL
serum	NULL
absorbed	NULL
antirabbit	NULL
IgG-AP	NULL
conjugate	NULL
and	NULL
APAAP	NULL
substrate	NULL
(	NULL
Vector	NULL
Labs	NULL
)	NULL
.	NULL

Sections	NULL
were	NULL
lightly	NULL
counterstained	NULL
with	NULL
haematoxylin	NULL
.	NULL

WESTERN	NULL
BLOT	NULL
ANALYSIS	NULL
OF	NULL
STAT	NULL
PROTEINS	NULL
STAT	NULL
expression	NULL
was	NULL
further	NULL
analysed	NULL
by	NULL
immunoblotting	NULL
of	NULL
immunoprecipitates	NULL
prepared	NULL
from	NULL
nuclear	NULL
and	NULL
cytosolic	NULL
cellular	NULL
extracts	NULL
from	NULL
spleen	NULL
and	NULL
pooled	NULL
lymph	NULL
node	NULL
lymphocyte	NULL
populations	NULL
.	NULL

Briefly	NULL
,	NULL
cytosolic	NULL
extracts	NULL
were	NULL
prepared	NULL
from	NULL
10**	NULL
cells	NULL
in	NULL
20	NULL
ul	NULL
lysis	NULL
buffer	NULL
A	NULL
(	NULL
10	NULL
mM	NULL
HEPES	NULL
,	NULL
1.5	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
10	NULL
mM	NULL
KCI	NULL
0.1	NULL
%	NULL
,	NULL
nonidet	NULL
P40	NULL
,	NULL
0.2	NULL
mM	NULL
PMSF	NULL
,	NULL
0.5	NULL
mM	NULL
DTT	NULL
)	NULL
pH	NULL
7.9	NULL
.	NULL

Nuclei	NULL
were	NULL
removed	NULL
by	NULL
centrifugation	NULL
and	NULL
supernatants	NULL
collected	NULL
as	NULL
the	NULL
cytoplasmic	NULL
fractions	NULL
.	NULL

Nuclei	NULL
were	NULL
then	NULL
incubated	NULL
in	NULL
20	NULL
pl	NULL
lysis	NULL
buffer	NULL
B	NULL
(	NULL
20	NULL
mM	NULL
HEPES	NULL
,	NULL
0.42M	NULL
NaCl	NULL
,	NULL
1.5	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
0.2	NULL
mM	NULL
EDTA	NULL
,	NULL
0.1	NULL
%	NULL
nonidet	NULL
P40	NULL
,	NULL
2	NULL
mM	NULL
PMSF	NULL
,	NULL
0.5	NULL
mM	NULL
DTT	NULL
)	NULL
pH	NULL
7.9	NULL
,	NULL
centri-fuged	NULL
,	NULL
and	NULL
supernatants	NULL
collected	NULL
as	NULL
nucleic	NULL
fractions	NULL
.	NULL

Protein	NULL
estimates	NULL
were	NULL
made	NULL
on	NULL
all	NULL
fractions	NULL
and	NULL
then	NULL
adjusted	NULL
to	NULL
contain	NULL
equivalent	NULL
protein	NULL
concentrations	NULL
,	NULL
thus	NULL
permitting	NULL
equal	NULL
loading	NULL
(	NULL
protein	NULL
amount	NULL
)	NULL
of	NULL
wells	NULL
.	NULL

STAT	NULL
4	NULL
or	NULL
STAT	NULL
6	NULL
associated	NULL
proteins	NULL
were	NULL
immunoprecipitated	NULL
by	NULL
anti-STAT	NULL
4	NULL
or	NULL
anti-STAT	NULL
6	NULL
antibodies	NULL
(	NULL
see	NULL
above	NULL
)	NULL
,	NULL
collected	NULL
on	NULL
Protein-A-sepharose	NULL
beads	NULL
(	NULL
Amersham-Pharmacia	NULL
)	NULL
and	NULL
resolved	NULL
by	NULL
SDS-PAGE	NULL
on	NULL
gradient	NULL
(	NULL
7-14	NULL
%	NULL
)	NULL
minigels	NULL
(	NULL
Pharmacia	NULL
,	NULL
Sweden	NULL
)	NULL
.	NULL

Protein	NULL
was	NULL
transferred	NULL
onto	NULL
Hybond	NULL
PVDF	NULL
membrane	NULL
T	NULL
cell	NULL
activation	NULL
in	NULL
mucosal	NULL
tolerance	NULL
induction	NULL
(	NULL
Amersham	NULL
Life	NULL
Science	NULL
)	NULL
by	NULL
electroblotting	NULL
.	NULL

Initial	NULL
probing	NULL
was	NULL
performed	NULL
for	NULL
phospho-tyrosine	NULL
(	NULL
PTY	NULL
)	NULL
(	NULL
mouse	NULL
anti-phosphotyrosine	NULL
mAb	NULL
4G10	NULL
;	NULL
Upstate	NULL
biotechnology	NULL
,	NULL
USA	NULL
)	NULL
detected	NULL
by	NULL
enhanced	NULL
chemiluminescence	NULL
(	NULL
ECL	NULL
)	NULL
with	NULL
rat	NULL
absorbed	NULL
anti-rabbit	NULL
IgG-HRP	NULL
conjugate	NULL
.	NULL

After	NULL
stripping	NULL
(	NULL
stripping	NULL
buffer	NULL
:	NULL
TRIS-HCl	NULL
pH	NULL
6.7	NULL
,	NULL
2	NULL
%	NULL
SDS	NULL
,	NULL
100	NULL
mM	NULL
2-mercaptoethanol	NULL
)	NULL
,	NULL
membranes	NULL
were	NULL
re-exposed	NULL
to	NULL
confirm	NULL
removal	NULL
of	NULL
signal	NULL
,	NULL
and	NULL
reprobed	NULL
for	NULL
further	NULL
analysis	NULL
of	NULL
STAT	NULL
4	NULL
,	NULL
6	NULL
or	NULL
STAT3	NULL
(	NULL
C20	NULL
Santa	NULL
Cruz	NULL
)	NULL
.	NULL

Preincubation	NULL
of	NULL
STAT	NULL
antibodies	NULL
with	NULL
blocking	NULL
peptides	NULL
was	NULL
used	NULL
to	NULL
control	NULL
for	NULL
specificity	NULL
of	NULL
the	NULL
signal	NULL
.	NULL

Results	NULL
SINGLE	NULL
DOSE	NULL
INTRANASAL	NULL
APPLICATION	NULL
OF	NULL
ALEXA-488	NULL
LABELLED	NULL
ANTIGEN	NULL
RAPIDLY	NULL
ACCUMULATES	NULL
WITHIN	NULL
REGIONAL	NULL
DRAINAGE	NULL
LYMPH	NULL
NODE	NULL
(	NULL
SCLN	NULL
)	NULL
AND	NULL
SPLEEN	NULL
ALLOWING	NULL
NAIVE	NULL
T	NULL
CELL	NULL
PRIMING	NULL
Following	NULL
direct	NULL
intranasal	NULL
administration	NULL
of	NULL
30	NULL
ul	NULL
Alexa-488	NULL
labelled	NULL
RE	NULL
,	NULL
animals	NULL
were	NULL
sacrificed	NULL
at	NULL
varying	NULL
time	NULL
points	NULL
and	NULL
spleen	NULL
and	NULL
SCLN	NULL
dissected	NULL
and	NULL
snap	NULL
frozen	NULL
for	NULL
subsequent	NULL
scanning	NULL
laser	NULL
confocal	NULL
microscopy	NULL
.	NULL

Figure	NULL
1	NULL
shows	NULL
that	NULL
by	NULL
30	NULL
minutes	NULL
Alexa-488	NULL
fluorescence	NULL
was	NULL
detected	NULL
within	NULL
both	NULL
SCLN	NULL
and	NULL
spleen	NULL
,	NULL
which	NULL
had	NULL
markedly	NULL
diminished	NULL
by	NULL
24	NULL
hours	NULL
.	NULL

Examination	NULL
of	NULL
other	NULL
lymph	NULL
nodes	NULL
(	NULL
submandibular	NULL
,	NULL
internal	NULL
jugular	NULL
,	NULL
parathyroid	NULL
,	NULL
mediastinal	NULL
,	NULL
and	NULL
mesenteric	NULL
)	NULL
indicated	NULL
the	NULL
antigen	NULL
also	NULL
reached	NULL
these	NULL
sites	NULL
with	NULL
similar	NULL
kinetics	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

By	NULL
24	NULL
hours	NULL
Alexa-488	NULL
RE	NULL
could	NULL
still	NULL
be	NULL
detected	NULL
within	NULL
cells	NULL
of	NULL
SCLN	NULL
(	NULL
Fig	NULL
1C	NULL
,	NULL
arrow	NULL
)	NULL
,	NULL
but	NULL
not	NULL
spleen	NULL
or	NULL
other	NULL
non-draining	NULL
nodes	NULL
,	NULL
although	NULL
systemic	NULL
presentation	NULL
of	NULL
antigen	NULL
was	NULL
evident	NULL
as	NULL
proliferative	NULL
T	NULL
cell	NULL
responses	NULL
could	NULL
be	NULL
elicited	NULL
from	NULL
both	NULL
SCLN	NULL
and	NULL
spleen	NULL
.	NULL

Naive	NULL
T	NULL
cell	NULL
priming	NULL
was	NULL
assessed	NULL
by	NULL
lymph	NULL
node	NULL
and	NULL
splenocyte	NULL
proliferative	NULL
responses	NULL
to	NULL
IRBP	NULL
.	NULL

Although	NULL
IRBP	NULL
is	NULL
a	NULL
known	NULL
immunogen	NULL
that	NULL
induces	NULL
EAU	NULL
,	NULL
when	NULL
administered	NULL
nasally	NULL
either	NULL
alone	NULL
or	NULL
within	NULL
RE	NULL
(	NULL
that	NULL
contains	NULL
4-8	NULL
%	NULL
of	NULL
IRBP	NULL
``	NULL
)	NULL
,	NULL
it	NULL
is	NULL
a	NULL
potent	NULL
A	NULL
B	NULL
C	NULL
24h	NULL
``	NULL
al	NULL
Cervical	NULL
LN	NULL
i	NULL
I	NULL
u	NULL
.	NULL

D	NULL
E.	NULL
F	NULL
Figure	NULL
1	NULL
-	NULL
Alexa-488	NULL
labelled	NULL
antigen	NULL
is	NULL
present	NULL
in	NULL
both	NULL
draining	NULL
LN	NULL
and	NULL
spleen	NULL
by	NULL
30	NULL
minutes	NULL
post-tolerisation	NULL
.	NULL

Figure	NULL
represents	NULL
merged	NULL
(	NULL
red	NULL
and	NULL
green	NULL
fluorescent	NULL
)	NULL
confocal	NULL
images	NULL
of	NULL
Alexa-488	NULL
labelled	NULL
S-Ag	NULL
accumulation	NULL
within	NULL
superficial	NULL
cervical	NULL
lymph	NULL
node	NULL
(	NULL
SCLN	NULL
)	NULL
,	NULL
top	NULL
panels	NULL
(	NULL
A-C	NULL
)	NULL
;	NULL
and	NULL
spleen	NULL
,	NULL
bottom	NULL
panels	NULL
(	NULL
D-F	NULL
)	NULL
,	NULL
following	NULL
intranasal	NULL
antigen	NULL
administration	NULL
.	NULL

By	NULL
30	NULL
minutes	NULL
green	NULL
fluorescing	NULL
antigen	NULL
was	NULL
detected	NULL
in	NULL
both	NULL
SCLN	NULL
and	NULL
spleen	NULL
and	NULL
was	NULL
maximal	NULL
by	NULL
4	NULL
hours	NULL
(	NULL
not	NULL
shown	NULL
,	NULL
FITC	NULL
488	NULL
nm	NULL
channel	NULL
saturated	NULL
)	NULL
.	NULL

At	NULL
24	NULL
hours	NULL
there	NULL
was	NULL
residual	NULL
detection	NULL
of	NULL
labelled	NULL
antigen	NULL
in	NULL
SCLN	NULL
(	NULL
arrow	NULL
)	NULL
present	NULL
in	NULL
green	NULL
channel	NULL
only	NULL
,	NULL
distinct	NULL
from	NULL
autofluorescent	NULL
tissue	NULL
resident	NULL
cells	NULL
detected	NULL
in	NULL
both	NULL
red	NULL
and	NULL
green	NULL
channels	NULL
,	NULL
which	NULL
appear	NULL
yellowlorange	NULL
.	NULL

www	NULL
.	NULL

bjophthalmol	NULL
.	NULL

com	NULL
1003	NULL
7	NULL
G	NULL
SCLN	NULL
6	NULL
M	NULL
Spleen	NULL
&	NULL
G	NULL
5	NULL
.E	NULL
c	NULL
4	NULL
503	NULL
=	NULL
]	NULL
E	NULL
-	NULL
2	NULL
0	NULL
ra	NULL
|	NULL
0	NULL
1h	NULL
24	NULL
h	NULL
48	NULL
h	NULL
96	NULL
h	NULL
Time	NULL
after	NULL
treatment	NULL
Figure	NULL
2	NULL
-	NULL
Antigen	NULL
specific	NULL
proliferation	NULL
in	NULL
both	NULL
SCLN	NULL
and	NULL
spleen	NULL
following	NULL
a	NULL
single	NULL
nasal	NULL
delivery	NULL
of	NULL
retinal	NULL
extract	NULL
.	NULL

Splenocyte	NULL
(	NULL
solid	NULL
bar	NULL
)	NULL
and	NULL
SCLN	NULL
(	NULL
open	NULL
bar	NULL
)	NULL
stimulation	NULL
by	NULL
IRBE	NULL
a	NULL
potent	NULL
tolerogen	NULL
in	NULL
RE	NULL
.	NULL

Histogram	NULL
represents	NULL
stimulation	NULL
index	NULL
(	NULL
Sl	NULL
;	NULL
mean	NULL
of	NULL
quadruplicate	NULL
cultures	NULL
with	NULL
stimulant	NULL
divided	NULL
by	NULL
mean	NULL
of	NULL
quadruplicate	NULL
control	NULL
cultures	NULL
)	NULL
.	NULL

Data	NULL
representative	NULL
of	NULL
three	NULL
similar	NULL
experiments	NULL
.	NULL

Maximum	NULL
Con	NULL
A	NULL
responses	NULL
were	NULL
21	NULL
745.8	NULL
(	NULL
SD	NULL
5420.7	NULL
)	NULL
in	NULL
lymph	NULL
node	NULL
and	NULL
110	NULL
750	NULL
(	NULL
21	NULL
745	NULL
)	NULL
in	NULL
spleen	NULL
.	NULL

Maximal	NULL
background	NULL
levels	NULL
were	NULL
468.3	NULL
(	NULL
226.8	NULL
)	NULL
in	NULL
SCLN	NULL
to	NULL
3991.5	NULL
(	NULL
188.5	NULL
)	NULL
in	NULL
spleen	NULL
.	NULL

By	NULL
48	NULL
hours	NULL
both	NULL
SCLN	NULL
and	NULL
spleen	NULL
generated	NULL
significant	NULL
proliferative	NULL
responses	NULL
to	NULL
IRBP	NULL
stimulation	NULL
(	NULL
SI	NULL
of	NULL
2.4	NULL
and	NULL
6.4	NULL
,	NULL
respectively	NULL
)	NULL
.	NULL

inducer	NULL
of	NULL
tolerance	NULL
,	NULL
protecting	NULL
against	NULL
RE	NULL
induced	NULL
EAU	NULL
.	NULL
``	NULL

Figure	NULL
2	NULL
shows	NULL
that	NULL
both	NULL
spleen	NULL
and	NULL
SCLN	NULL
show	NULL
significant	NULL
proliferative	NULL
responses	NULL
to	NULL
IRBP	NULL
(	NULL
SI	NULL
of	NULL
2.4	NULL
rising	NULL
to	NULL
3.5	NULL
at	NULL
96	NULL
hours	NULL
for	NULL
SCLN	NULL
and	NULL
an	NULL
SI	NULL
of	NULL
6.4	NULL
for	NULL
spleen	NULL
at	NULL
48	NULL
hours	NULL
)	NULL
;	NULL
data	NULL
representative	NULL
of	NULL
three	NULL
separate	NULL
experiments	NULL
)	NULL
by	NULL
48	NULL
hours	NULL
after	NULL
intranasal	NULL
antigen	NULL
administration	NULL
.	NULL

ADMINISTRATION	NULL
OF	NULL
RETINAL	NULL
ANTIGEN	NULL
INTRANASALLY	NULL
GENERATES	NULL
CHANGES	NULL
IN	NULL
STAT	NULL
TRANSCRIPTION	NULL
FACTORS	NULL
We	NULL
have	NULL
previously	NULL
observed	NULL
that	NULL
repeated	NULL
intranasal	NULL
doses	NULL
of	NULL
retinal	NULL
antigen	NULL
induce	NULL
an	NULL
IFN-y	NULL
burst	NULL
with	NULL
increased	NULL
CD4+	NULL
T	NULL
cells	NULL
numbers	NULL
within	NULL
SCLN	NULL
but	NULL
not	NULL
spleen	NULL
,	NULL
and	NULL
that	NULL
on	NULL
subsequent	NULL
antigen	NULL
challenge	NULL
there	NULL
is	NULL
increased	NULL
T	NULL
cell	NULL
apoptosis	NULL
in	NULL
SCLN	NULL
.	NULL
``	NULL

We	NULL
wished	NULL
to	NULL
ascertain	NULL
the	NULL
overall	NULL
effect	NULL
of	NULL
cytokine	NULL
signalling	NULL
in	NULL
the	NULL
tissues	NULL
following	NULL
a	NULL
single	NULL
intranasal	NULL
application	NULL
of	NULL
antigen	NULL
which	NULL
might	NULL
be	NULL
associated	NULL
with	NULL
our	NULL
observed	NULL
previous	NULL
changes	NULL
and	NULL
the	NULL
T	NULL
cell	NULL
proliferation	NULL
responses	NULL
we	NULL
had	NULL
currently	NULL
noted	NULL
.	NULL

STAT	NULL
6	NULL
and	NULL
STAT4	NULL
mediate	NULL
specific	NULL
IL-4	NULL
and	NULL
IL-12	NULL
signalling	NULL
respectively	NULL
,	NULL
and	NULL
are	NULL
important	NULL
regulators	NULL
of	NULL
T	NULL
cell	NULL
function	NULL
.	NULL
``	NULL

Experiments	NULL
were	NULL
therefore	NULL
repeated	NULL
and	NULL
SCLN	NULL
and	NULL
spleen	NULL
were	NULL
analysed	NULL
for	NULL
evidence	NULL
of	NULL
Thl	NULL
(	NULL
IL-12	NULL
mediated	NULL
STAT	NULL
4	NULL
activation	NULL
)	NULL
or	NULL
Th2	NULL
type	NULL
cell	NULL
activation	NULL
(	NULL
IL-4	NULL
mediated	NULL
STAT	NULL
6	NULL
activation	NULL
)	NULL
at	NULL
varying	NULL
times	NULL
following	NULL
a	NULL
single	NULL
intranasal	NULL
application	NULL
of	NULL
retinal	NULL
antigen	NULL
.	NULL

Figure	NULL
3	NULL
shows	NULL
kinetics	NULL
in	NULL
STAT	NULL
expression	NULL
in	NULL
tissue	NULL
.	NULL

In	NULL
SCLN	NULL
,	NULL
STAT	NULL
6	NULL
expression	NULL
appeared	NULL
to	NULL
diminish	NULL
over	NULL
first	NULL
24	NULL
hours	NULL
after	NULL
intranasal	NULL
administration	NULL
,	NULL
whereas	NULL
STAT	NULL
4	NULL
expression	NULL
(	NULL
low	NULL
in	NULL
normal	NULL
SCLN	NULL
)	NULL
peaked	NULL
at	NULL
24	NULL
hours	NULL
.	NULL

In	NULL
spleen	NULL
both	NULL
STAT	NULL
4	NULL
and	NULL
6	NULL
expression	NULL
increased	NULL
over	NULL
96	NULL
hours	NULL
.	NULL

Upregulation	NULL
of	NULL
STAT	NULL
4	NULL
at	NULL
24	NULL
hours	NULL
after	NULL
treatment	NULL
was	NULL
not	NULL
observed	NULL
in	NULL
the	NULL
submandibular	NULL
or	NULL
mesenteric	NULL
nodes	NULL
.	NULL

The	NULL
change	NULL
in	NULL
STAT	NULL
patterns	NULL
of	NULL
expression	NULL
were	NULL
further	NULL
investigated	NULL
for	NULL
evidence	NULL
of	NULL
activation	NULL
(	NULL
nuclear	NULL
translocation	NULL
)	NULL
by	NULL
western	NULL
Dick	NULL
,	NULL
Sharma	NULL
,	NULL
Liversidge	NULL
Cervical	NULL
lymph	NULL
node	NULL
Oh	NULL
STAT	NULL
6	NULL
STAT	NULL
4	NULL
96h	NULL
96h	NULL
Spleen	NULL
0h	NULL
24h	NULL
|-	NULL
[	NULL
Yon	NULL
~	NULL
.	NULL

~~	NULL
€	NULL
.	NULL

``	NULL
t	NULL
®	NULL
Rating	NULL
.	NULL

STAT	NULL
6	NULL
#	NULL
Fik	NULL
|	NULL
Oh	NULL
STAT	NULL
4	NULL
Figure	NULL
3	NULL
-	NULL
STAT	NULL
4	NULL
expression	NULL
transiently	NULL
increases	NULL
over	NULL
24	NULL
hours	NULL
in	NULL
SCLN	NULL
APAAP	NULL
immunohistochemical	NULL
analysis	NULL
of	NULL
STAT	NULL
4	NULL
and	NULL
6	NULL
expression	NULL
in	NULL
SCLN	NULL
and	NULL
spleen	NULL
following	NULL
antigen	NULL
nasal	NULL
delivery	NULL
.	NULL

A	NULL
transient	NULL
increase	NULL
in	NULL
expression	NULL
of	NULL
STAT	NULL
4	NULL
with	NULL
decreased	NULL
STAT	NULL
6	NULL
expression	NULL
occurred	NULL
at	NULL
24	NULL
hours	NULL
in	NULL
cervical	NULL
lymph	NULL
nodes	NULL
(	NULL
SCLN	NULL
)	NULL
(	NULL
all	NULL
x125	NULL
)	NULL
,	NULL
followed	NULL
by	NULL
a	NULL
reduction	NULL
in	NULL
STAT	NULL
4	NULL
by	NULL
96	NULL
hours	NULL
(	NULL
X62.5	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
spleen	NULL
showed	NULL
weak	NULL
constitutive	NULL
expression	NULL
of	NULL
both	NULL
STAT	NULL
4	NULL
and	NULL
STAT6	NULL
(	NULL
0	NULL
hours	NULL
)	NULL
(	NULL
62.5	NULL
)	NULL
although	NULL
this	NULL
was	NULL
increased	NULL
at	NULL
later	NULL
time	NULL
points	NULL
,	NULL
with	NULL
strong	NULL
,	NULL
focal	NULL
expression	NULL
of	NULL
both	NULL
at	NULL
96	NULL
hours	NULL
after	NULL
treatment	NULL
(	NULL
x125	NULL
)	NULL
.	NULL

Controls	NULL
with	NULL
appropriate	NULL
blocking	NULL
peptides	NULL
did	NULL
not	NULL
demonstrate	NULL
any	NULL
STAT	NULL
expression	NULL
or	NULL
background	NULL
colour	NULL
.	NULL

Data	NULL
representative	NULL
of	NULL
three	NULL
separate	NULL
experiments	NULL
.	NULL

blotting	NULL
of	NULL
STAT	NULL
4	NULL
and	NULL
STAT	NULL
6	NULL
immunoprecipitates	NULL
from	NULL
cytoplasmic	NULL
and	NULL
nuclear	NULL
extracts	NULL
of	NULL
SCLN	NULL
and	NULL
spleen	NULL
.	NULL

Because	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
STAT	NULL
proteins	NULL
is	NULL
associated	NULL
with	NULL
,	NULL
and	NULL
is	NULL
required	NULL
,	NULL
for	NULL
the	NULL
binding	NULL
of	NULL
STAT	NULL
's	NULL
to	NULL
conserved	NULL
promoter	NULL
elements	NULL
within	NULL
the	NULL
nucleus	NULL
anti-phosphotyrosine	NULL
(	NULL
PTY	NULL
)	NULL
,	NULL
immunoblotting	NULL
was	NULL
also	NULL
carried	NULL
out	NULL
.	NULL

Figure	NULL
4	NULL
shows	NULL
that	NULL
STAT	NULL
6	NULL
protein	NULL
expression	NULL
in	NULL
SCLIN	NULL
was	NULL
generally	NULL
low	NULL
and	NULL
fluctuated	NULL
in	NULL
cytoplasmic	NULL
extracts	NULL
,	NULL
and	NULL
although	NULL
higher	NULL
expression	NULL
was	NULL
found	NULL
in	NULL
spleen	NULL
nuclear	NULL
extracts	NULL
,	NULL
this	NULL
appeared	NULL
to	NULL
be	NULL
constitutive	NULL
and	NULL
was	NULL
not	NULL
phosphorylated	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
STAT	NULL
4	NULL
and	NULL
coprecipitated	NULL
STAT	NULL
3	NULL
expression	NULL
appeared	NULL
to	NULL
fall	NULL
in	NULL
the	NULL
SCLN	NULL
cytoplasm	NULL
,	NULL
suggesting	NULL
dissociation	NULL
of	NULL
heterodimers	NULL
with	NULL
time	NULL
,	NULL
although	NULL
notably	NULL
,	NULL
STATA/STAT3	NULL
heterodimers	NULL
increased	NULL
in	NULL
cytoplasmic	NULL
extracts	NULL
from	NULL
spleen	NULL
at	NULL
24	NULL
hours	NULL
.	NULL

STAT	NULL
4	NULL
expression	NULL
in	NULL
the	NULL
nuclear	NULL
extracts	NULL
remained	NULL
strong	NULL
and	NULL
was	NULL
not	NULL
associated	NULL
with	NULL
STAT	NULL
3	NULL
after	NULL
treatment	NULL
.	NULL

STAT	NULL
4	NULL
immunoprecipitates	NULL
were	NULL
tyrosine	NULL
phosphorylated	NULL
.	NULL

www	NULL
.	NULL

bjophthalmol	NULL
.	NULL

com	NULL
Discussion	NULL
Evidence	NULL
to	NULL
date	NULL
supports	NULL
distinct	NULL
mechanistic	NULL
differences	NULL
in	NULL
tolerance	NULL
induction	NULL
between	NULL
nasal	NULL
and	NULL
systemic	NULL
antigen	NULL
delivery	NULL
,	NULL
primarily	NULL
because	NULL
without	NULL
drainage	NULL
lymph	NULL
nodes	NULL
,	NULL
tolerance	NULL
is	NULL
abrogated	NULL
.	NULL

Such	NULL
inference	NULL
is	NULL
supported	NULL
by	NULL
the	NULL
many	NULL
reports	NULL
that	NULL
have	NULL
shown	NULL
the	NULL
nasal	NULL
compartment	NULL
as	NULL
an	NULL
extremely	NULL
efficient	NULL
route	NULL
for	NULL
tolerance	NULL
induction	NULL
to	NULL
both	NULL
non-pathogenic	NULL
and	NULL
autoantigens	NULL
.	NULL

The	NULL
unique	NULL
microenvironment	NULL
that	NULL
includes	NULL
not	NULL
only	NULL
the	NULL
regional	NULL
drainage	NULL
lymph	NULL
nodes	NULL
``	NULL
but	NULL
also	NULL
the	NULL
nasorespiratory	NULL
mucosa	NULL
and	NULL
its	NULL
resident	NULL
cells	NULL
(	NULL
for	NULL
example	NULL
,	NULL
RTDC	NULL
)	NULL
``	NULL
*	NULL
*	NULL
are	NULL
therefore	NULL
highly	NULL
selected	NULL
for	NULL
tolerance	NULL
induction	NULL
.	NULL

Until	NULL
recently	NULL
the	NULL
kinetics	NULL
of	NULL
such	NULL
responses	NULL
have	NULL
been	NULL
poorly	NULL
under-stood	NULL
.	NULL
``	NULL

Following	NULL
intranasal	NULL
delivery	NULL
of	NULL
titri-ated	NULL
tolerogenic	NULL
peptide	NULL
of	NULL
myelin	NULL
basic	NULL
protein	NULL
(	NULL
MBP	NULL
)	NULL
,	NULL
[	NULL
3H	NULL
]	NULL
JAc1-9	NULL
[	NULL
4y	NULL
]	NULL
,	NULL
concentrations	NULL
(	NULL
as	NULL
well	NULL
as	NULL
presence	NULL
of	NULL
intact	NULL
peptide	NULL
)	NULL
were	NULL
high	NULL
in	NULL
draining	NULL
lymph	NULL
nodes	NULL
and	NULL
spleen	NULL
between	NULL
2.5-4	NULL
hours	NULL
of	NULL
peptide	NULL
delivery	NULL
and	NULL
significant	NULL
levels	NULL
were	NULL
observed	NULL
in	NULL
blood	NULL
and	NULL
T	NULL
cell	NULL
activation	NULL
in	NULL
mucosal	NULL
tolerance	NULL
induction	NULL
Cytoplasmic	NULL
extract	NULL
Nuclear	NULL
extract	NULL
LN	NULL
Spleen	NULL
LN	NULL
Spleen	NULL
IP	NULL
Ab	NULL
1	NULL
20	NULL
3	NULL
40	NULL
50	NULL
6	NULL
1	NULL
2	NULL
3	NULL
40	NULL
50	NULL
6	NULL
stAT6	NULL
_	NULL
stAtTs	NULL
|	NULL
=	NULL
s	NULL
H	NULL
collins	NULL
|	NULL
PTY	NULL
``	NULL
e	NULL
ii	NULL
|	NULL
stata	NULL
!	NULL

!	NULL

stat4	NULL
|	NULL
``	NULL
-	NULL
'	NULL
--	NULL
H-	NULL
``	NULL
``	NULL
-+	NULL
]	NULL
STAT	NULL
3	NULL
|	NULL
«	NULL
«	NULL
-	NULL
a	NULL
»	NULL
||	NULL
|	NULL
prv	NULL
-	NULL
|	NULL
@	NULL
a	NULL
@	NULL
lMge	NULL
||	NULL
ape	NULL
-	NULL
&	NULL
th	NULL
4s	NULL
|	NULL
0	NULL
40	NULL
24	NULL
0	NULL
40	NULL
24	NULL
0	NULL
4	NULL
24	NULL
0	NULL
4	NULL
24	NULL
Hours	NULL
post	NULL
treatment	NULL
Figure	NULL
4	NULL
-	NULL
Western	NULL
blot	NULL
analysis	NULL
of	NULL
phosphorylation	NULL
and	NULL
heterodimer	NULL
formation	NULL
by	NULL
STAT4	NULL
and	NULL
STAT6	NULL
in	NULL
both	NULL
SCLN	NULL
and	NULL
spleen	NULL
following	NULL
a	NULL
single	NULL
nasal	NULL
delivery	NULL
of	NULL
retinal	NULL
extract	NULL
.	NULL

STAT	NULL
6	NULL
or	NULL
STAT4	NULL
and	NULL
associated	NULL
proteins	NULL
(	NULL
STAT3	NULL
)	NULL
were	NULL
immunoprecipitated	NULL
(	NULL
IP	NULL
)	NULL
from	NULL
cytoplasmic	NULL
and	NULL
nuclear	NULL
extracts	NULL
from	NULL
SCLN	NULL
and	NULL
spleens	NULL
from	NULL
rats	NULL
at	NULL
0	NULL
,	NULL
4	NULL
,	NULL
and	NULL
24	NULL
hours	NULL
after	NULL
intranasal	NULL
delivery	NULL
of	NULL
RE	NULL
antigen	NULL
.	NULL

Equivalent	NULL
quantities	NULL
of	NULL
protein	NULL
were	NULL
run	NULL
on	NULL
SDS	NULL
gel	NULL
(	NULL
lanes	NULL
1-6	NULL
)	NULL
,	NULL
blotted	NULL
onto	NULL
nitrocellulose	NULL
,	NULL
and	NULL
probed	NULL
with	NULL
antibody	NULL
4G10	NULL
to	NULL
detect	NULL
phosporylated	NULL
tyrosine	NULL
residues	NULL
(	NULL
PTY	NULL
)	NULL
.	NULL

Blots	NULL
were	NULL
the	NULL
stripped	NULL
and	NULL
reprobed	NULL
for	NULL
STAT	NULL
proteins	NULL
as	NULL
indicated	NULL
.	NULL

Immunoblot	NULL
analysis	NULL
of	NULL
resolved	NULL
proteins	NULL
indicated	NULL
STAT	NULL
4	NULL
phosphorylation	NULL
(	NULL
PTY	NULL
)	NULL
in	NULL
both	NULL
cytoplasmic	NULL
and	NULL
nuclear	NULL
extracts	NULL
at	NULL
all	NULL
time	NULL
points	NULL
.	NULL

Phosphorylation	NULL
of	NULL
STAT6	NULL
proteins	NULL
was	NULL
very	NULL
weak	NULL
or	NULL
absent	NULL
by	NULL
comparison	NULL
.	NULL

Some	NULL
STAT4/STAT3	NULL
heterodimers	NULL
were	NULL
constitutively	NULL
present	NULL
but	NULL
these	NULL
appeared	NULL
to	NULL
dissociate	NULL
over	NULL
time	NULL
,	NULL
with	NULL
the	NULL
exception	NULL
of	NULL
spleen	NULL
cytoplasm	NULL
at	NULL
24	NULL
hours	NULL
after	NULL
treatment	NULL
which	NULL
stained	NULL
strongly	NULL
for	NULL
co-precipitated	NULL
STAT3	NULL
.	NULL

STAT4/STAT3	NULL
heterodimers	NULL
were	NULL
detectable	NULL
in	NULL
the	NULL
SCLN	NULL
nuclet	NULL
of	NULL
normal	NULL
but	NULL
not	NULL
treated	NULL
rats	NULL
.	NULL

IP	NULL
denotes	NULL
antibody	NULL
used	NULL
to	NULL
immunoprecipate	NULL
protein	NULL
,	NULL
Ab	NULL
denotes	NULL
antibody	NULL
used	NULL
to	NULL
stain	NULL
blot	NULL
.	NULL

lymphatics	NULL
,	NULL
peaking	NULL
at	NULL
around	NULL
4	NULL
hours	NULL
.	NULL

Our	NULL
present	NULL
data	NULL
also	NULL
support	NULL
rapid	NULL
traffic	NULL
of	NULL
antigen	NULL
from	NULL
the	NULL
nasal	NULL
mucosa	NULL
to	NULL
drainage	NULL
lymph	NULL
nodes	NULL
and	NULL
spleen	NULL
,	NULL
as	NULL
early	NULL
as	NULL
30	NULL
minutes	NULL
after	NULL
delivery	NULL
(	NULL
Fig	NULL
1	NULL
)	NULL
.	NULL

One	NULL
of	NULL
the	NULL
major	NULL
mechanisms	NULL
of	NULL
active	NULL
suppression	NULL
in	NULL
mucosal	NULL
tolerance	NULL
highlighted	NULL
to	NULL
date	NULL
is	NULL
the	NULL
generation	NULL
regulatory	NULL
T	NULL
cells	NULL
.	NULL
``	NULL

``	NULL
However	NULL
,	NULL
the	NULL
cellular	NULL
mechanisms	NULL
preceding	NULL
either	NULL
active	NULL
suppressor	NULL
mechanisms	NULL
or	NULL
T	NULL
cell	NULL
anergy/deletion	NULL
in	NULL
EAU	NULL
are	NULL
not	NULL
fully	NULL
identified	NULL
.	NULL

Application	NULL
of	NULL
soluble	NULL
antigens	NULL
via	NULL
mucosal	NULL
surfaces	NULL
leads	NULL
to	NULL
a	NULL
transient	NULL
activation	NULL
of	NULL
T	NULL
cells	NULL
in	NULL
the	NULL
drainage	NULL
lymph	NULL
nodes	NULL
and	NULL
Peyer	NULL
's	NULL
patches	NULL
of	NULL
the	NULL
gut	NULL
and	NULL
apoptosis	NULL
``	NULL
(	NULL
reviewed	NULL
by	NULL
Lowrey	NULL
et	NULL
aP	NULL
and	NULL
Wardrop	NULL
and	NULL
Whitacre	NULL
``	NULL
)	NULL
.	NULL

Such	NULL
activation	NULL
induced	NULL
cell	NULL
deletion	NULL
is	NULL
not	NULL
complete	NULL
and	NULL
the	NULL
resulting	NULL
T	NULL
cell	NULL
populations	NULL
are	NULL
unresponsive	NULL
to	NULL
further	NULL
stimulation	NULL
``	NULL
but	NULL
may	NULL
still	NULL
produce	NULL
IL-10	NULL
.	NULL
``	NULL

``	NULL
Further	NULL
to	NULL
our	NULL
previous	NULL
reports	NULL
of	NULL
T	NULL
cell	NULL
activation	NULL
and	NULL
apoptosis	NULL
within	NULL
SCLN	NULL
following	NULL
repeated	NULL
intranasal	NULL
antigen	NULL
administration	NULL
,	NULL
we	NULL
now	NULL
show	NULL
that	NULL
even	NULL
a	NULL
single	NULL
dose	NULL
(	NULL
able	NULL
to	NULL
actively	NULL
suppress	NULL
EAU*	NULL
``	NULL
)	NULL
of	NULL
retinal	NULL
extract	NULL
(	NULL
a	NULL
mixture	NULL
of	NULL
soluble	NULL
retinal	NULL
antigens	NULL
)	NULL
,	NULL
results	NULL
in	NULL
a	NULL
predominance	NULL
of	NULL
phosphorylated	NULL
STAT4	NULL
in	NULL
both	NULL
SCLN	NULL
and	NULL
spleen	NULL
and	NULL
T	NULL
cell	NULL
priming	NULL
and	NULL
proliferation	NULL
to	NULL
IRBP	NULL
,	NULL
a	NULL
major	NULL
tolerogen	NULL
``	NULL
'	NULL
within	NULL
retinal	NULL
extract	NULL
.	NULL

As	NULL
STAT4	NULL
is	NULL
highly	NULL
phosphorylated	NULL
within	NULL
5	NULL
minutes	NULL
of	NULL
IL-12	NULL
receptor	NULL
engage-ment	NULL
,	NULL
constitutive	NULL
expression	NULL
of	NULL
the	NULL
activated	NULL
form	NULL
of	NULL
this	NULL
STAT	NULL
within	NULL
the	NULL
lymphoid	NULL
tissues	NULL
of	NULL
normally	NULL
housed	NULL
rats	NULL
(	NULL
non-SPF	NULL
condition	NULL
)	NULL
is	NULL
perhaps	NULL
not	NULL
surprising	NULL
.	NULL
``	NULL

Co-precipitation	NULL
of	NULL
STAT3	NULL
with	NULL
STAT4	NULL
heterodimers	NULL
as	NULL
well	NULL
as	NULL
formation	NULL
of	NULL
STAT	NULL
4	NULL
homodimers	NULL
is	NULL
specific	NULL
to	NULL
IL-12	NULL
signalling	NULL
and	NULL
results	NULL
in	NULL
augmented	NULL
IFN-y	NULL
secretion	NULL
from	NULL
Thl	NULL
cells	NULL
.	NULL
``	NULL

The	NULL
reduction	NULL
in	NULL
co-precipitated	NULL
STAT3	NULL
protein	NULL
over	NULL
24	NULL
hours	NULL
in	NULL
the	NULL
SCLN	NULL
and	NULL
absence	NULL
of	NULL
STAT3	NULL
www	NULL
.	NULL

bjophthalmol	NULL
.	NULL

com	NULL
1005	NULL
from	NULL
the	NULL
nuclear	NULL
fraction	NULL
of	NULL
treated	NULL
lymphoid	NULL
tissues	NULL
is	NULL
consistent	NULL
with	NULL
a	NULL
reduction	NULL
or	NULL
dissociation	NULL
of	NULL
heterodimer	NULL
formation	NULL
,	NULL
and	NULL
may	NULL
represent	NULL
an	NULL
association	NULL
of	NULL
STAT4	NULL
with	NULL
another	NULL
component	NULL
.	NULL

One	NULL
notion	NULL
is	NULL
that	NULL
our	NULL
observed	NULL
early	NULL
proliferative	NULL
responses	NULL
and	NULL
STAT	NULL
activation	NULL
may	NULL
represent	NULL
inductive	NULL
events	NULL
that	NULL
lead	NULL
to	NULL
antigen	NULL
stimulated	NULL
Th1	NULL
cell	NULL
anergy	NULL
.	NULL

Antigen	NULL
stimulated	NULL
Thl	NULL
anergy	NULL
has	NULL
been	NULL
related	NULL
to	NULL
increased	NULL
levels	NULL
of	NULL
p27/Kipl	NULL
cyclin	NULL
dependent	NULL
kinase	NULL
inhibitors	NULL
``	NULL
and	NULL
we	NULL
are	NULL
presently	NULL
investigating	NULL
such	NULL
possibilities	NULL
in	NULL
mucosal	NULL
tolerance	NULL
induction	NULL
.	NULL

The	NULL
significance	NULL
of	NULL
the	NULL
increase	NULL
in	NULL
STAT3/STAT	NULL
4	NULL
heterodimers	NULL
at	NULL
24	NULL
hours	NULL
in	NULL
spleen	NULL
cytoplasmic	NULL
fractions	NULL
is	NULL
currently	NULL
unexplained	NULL
.	NULL

It	NULL
may	NULL
represent	NULL
additional	NULL
signalling	NULL
input	NULL
to	NULL
the	NULL
spleen	NULL
as	NULL
several	NULL
cytokines	NULL
including	NULL
IL-10	NULL
are	NULL
known	NULL
to	NULL
activate	NULL
STAT3	NULL
.	NULL

Increased	NULL
availability	NULL
of	NULL
phosphorylated	NULL
STAT	NULL
3	NULL
may	NULL
enable	NULL
increased	NULL
heterodimer	NULL
formation	NULL
.	NULL

A	NULL
mechanism	NULL
of	NULL
a	NULL
potentially	NULL
stable	NULL
ThZ2	NULL
commitment	NULL
remains	NULL
obscure	NULL
,	NULL
but	NULL
non-phosphorylation	NULL
of	NULL
STAT6	NULL
in	NULL
our	NULL
model	NULL
would	NULL
suggest	NULL
that	NULL
IL-4	NULL
dependent	NULL
signalling	NULL
is	NULL
not	NULL
involved	NULL
in	NULL
the	NULL
initial	NULL
24	NULL
hours	NULL
following	NULL
intranasal	NULL
exposure	NULL
to	NULL
antigen	NULL
.	NULL

STAT6	NULL
is	NULL
expressed	NULL
in	NULL
a	NULL
wide	NULL
range	NULL
of	NULL
cell	NULL
types	NULL
and	NULL
the	NULL
patterns	NULL
of	NULL
expression	NULL
revealed	NULL
by	NULL
immunostaining	NULL
of	NULL
lymphoid	NULL
tissue	NULL
staining	NULL
reflect	NULL
this	NULL
.	NULL

The	NULL
data	NULL
generated	NULL
following	NULL
a	NULL
single	NULL
intranasal	NULL
application	NULL
of	NULL
autoantigen	NULL
does	NULL
not	NULL
support	NULL
the	NULL
notion	NULL
of	NULL
a	NULL
Thl	NULL
to	NULL
Th2	NULL
CD4+	NULL
T	NULL
cell	NULL
switch	NULL
mediated	NULL
via	NULL
default	NULL
``	NULL
Th2	NULL
polarity	NULL
``	NULL
of	NULL
RTDC	NULL
function	NULL
during	NULL
T	NULL
cell	NULL
priming	NULL
as	NULL
previously	NULL
proposed	NULL
during	NULL
allergic	NULL
re-sponses	NULL
.	NULL
``	NULL

Whether	NULL
IL-4	NULL
activated	NULL
STAT6	NULL
or	NULL
other	NULL
associated	NULL
molecules	NULL
are	NULL
involved	NULL
during	NULL
tolerance	NULL
induction	NULL
by	NULL
repetitive	NULL
low	NULL
dose	NULL
antigen	NULL
administration	NULL
remains	NULL
to	NULL
be	NULL
elucidated	NULL
.	NULL

What	NULL
is	NULL
well	NULL
appreciated	NULL
is	NULL
the	NULL
involvement	NULL
of	NULL
cytokine	NULL
activated	NULL
STAT	NULL
molecules	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
T	NULL
helper	NULL
cell	NULL
differentiation	NULL
and	NULL
apoptosis	NULL
,	NULL
``	NULL
and	NULL
the	NULL
ability	NULL
of	NULL
regulatory	NULL
cytokines	NULL
such	NULL
as	NULL
TGF-B	NULL
to	NULL
modulate	NULL
this	NULL
process	NULL
.	NULL
``	NULL

Despite	NULL
previously	NULL
demonstrating	NULL
,	NULL
after	NULL
tolerance	NULL
induction	NULL
and	NULL
immunisation	NULL
,	NULL
Th2	NULL
responses	NULL
(	NULL
IL-2	NULL
and	NULL
IL-10	NULL
producing	NULL
)	NULL
from	NULL
infiltrating	NULL
T	NULL
cells	NULL
within	NULL
retina	NULL
,	NULL
``	NULL
there	NULL
remains	NULL
little	NULL
evidence	NULL
to	NULL
support	NULL
a	NULL
bias	NULL
toward	NULL
Th2	NULL
responses	NULL
as	NULL
a	NULL
direct	NULL
result	NULL
of	NULL
tolerance	NULL
mechanisms	NULL
within	NULL
the	NULL
lymph	NULL
node	NULL
.	NULL
``	NULL

Here	NULL
we	NULL
have	NULL
shown	NULL
increased	NULL
STAT4	NULL
signalling	NULL
,	NULL
concomitant	NULL
with	NULL
antigen	NULL
specific	NULL
proliferation	NULL
,	NULL
signifying	NULL
Th1	NULL
reactivity	NULL
and	NULL
is	NULL
in	NULL
keeping	NULL
with	NULL
our	NULL
previous	NULL
data	NULL
of	NULL
a	NULL
transient	NULL
IFN-y	NULL
burst	NULL
within	NULL
SCLN®	NULL
and	NULL
supports	NULL
an	NULL
initial	NULL
T	NULL
cell	NULL
activating	NULL
event	NULL
.	NULL

Together	NULL
with	NULL
the	NULL
observation	NULL
by	NULL
Burkhart	NULL
et	NULL
a/	NULL
``	NULL
that	NULL
IFN-y	NULL
and	NULL
IL-4	NULL
cytokine	NULL
production	NULL
followed	NULL
different	NULL
kinetics	NULL
in	NULL
cervical	NULL
lymph	NULL
nodes	NULL
and	NULL
spleen	NULL
,	NULL
our	NULL
data	NULL
support	NULL
the	NULL
possibility	NULL
of	NULL
separate	NULL
roles	NULL
for	NULL
SCLN	NULL
and	NULL
spleen	NULL
in	NULL
the	NULL
induction	NULL
of	NULL
nasal	NULL
tol-erance	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
a	NULL
grant	NULL
from	NULL
WH	NULL
Ross	NULL
Foundation	NULL
for	NULL
the	NULL
Prevention	NULL
of	NULL
Blindness	NULL
,	NULL
Scotland	NULL
.	NULL

We	NULL
would	NULL
like	NULL
to	NULL
thank	NULL
Zoe	NULL
Fletcher	NULL
,	NULL
Linda	NULL
Duncan	NULL
,	NULL
Rosemary	NULL
Dawson	NULL
,	NULL
and	NULL
Neil	NULL
Taylor	NULL
for	NULL
expert	NULL
technical	NULL
assistance	NULL
.	NULL

1006	NULL
bo	NULL
wo	NULL
im	NULL
un	NULL
&	NULL
10	NULL
1	NULL
w	NULL
12	NULL
13	NULL
14	NULL
15	NULL
16	NULL
17	NULL
18	NULL
19	NULL
20	NULL
Xiao	NULL
BG	NULL
,	NULL
Link	NULL
H.	NULL
Mucosal	NULL
tolerance	NULL
:	NULL
a	NULL
two	NULL
edged	NULL
sword	NULL
to	NULL
prevent	NULL
and	NULL
treat	NULL
autoimmune	NULL
diseases	NULL
.	NULL

Clin	NULL
Immunol	NULL
Immunopathol	NULL
1997	NULL
;	NULL
85:119-28	NULL
.	NULL

Lowrey	NULL
JL	NULL
,	NULL
Savage	NULL
ND	NULL
,	NULL
Palliser	NULL
D	NULL
;	NULL
et	NULL
al	NULL
.	NULL

Induction	NULL
of	NULL
tolerance	NULL
via	NULL
the	NULL
respiratory	NULL
mucosa	NULL
.	NULL

Int	NULL
Arch	NULL
.	NULL

Allergy	NULL
Immunol	NULL
1998	NULL
;	NULL
116:93-102	NULL
.	NULL

Wardrop	NULL
RM	NULL
,	NULL
Whitacre	NULL
CC	NULL
.	NULL

Oral	NULL
tolerance	NULL
in	NULL
the	NULL
treatment	NULL
of	NULL
inflammatory	NULL
autoimmune	NULL
diseases	NULL
.	NULL

Inflamm	NULL
:	NULL
Res	NULL
1999	NULL
;	NULL
48:106-19	NULL
.	NULL

Forrester	NULL
JV	NULL
,	NULL
Liversidge	NULL
J	NULL
,	NULL
Dua	NULL
HS	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Comparison	NULL
of	NULL
clinical	NULL
and	NULL
experimental	NULL
uveitis	NULL
.	NULL

Curr	NULL
Eye	NULL
Res	NULL
1990	NULL
;	NULL
9:75-	NULL
chk	NULL
AD	NULL
,	NULL
Cheng	NULL
YF	NULL
,	NULL
Liversidge	NULL
,	NULL
J	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Intranasal	NULL
administration	NULL
of	NULL
retinal	NULL
antigens	NULL
suppresses	NULL
retinal	NULL
antigen-induced	NULL
experimental	NULL
autoimmune	NULL
uveoretinitis	NULL
.	NULL

Immunology	NULL
1994	NULL
;	NULL
82:625-31	NULL
.	NULL

Nussenblatt	NULL
RB	NULL
,	NULL
Caspi	NULL
RR	NULL
,	NULL
Mahdi	NULL
R	NULL
,	NULL
e	NULL
al	NULL
.	NULL

Inhibition	NULL
of	NULL
S-Ag	NULL
induced	NULL
experimental	NULL
autoimmune	NULL
uveoretinitis	NULL
by	NULL
oral	NULL
induction	NULL
of	NULL
tolerance	NULL
with	NULL
S-Ag	NULL
.	NULL

7	NULL
Immunol	NULL
1990	NULL
;	NULL
144	NULL
:	NULL
1689-95	NULL
.	NULL

Dua	NULL
HS	NULL
,	NULL
Gomes	NULL
JAP	NULL
,	NULL
Jindal	NULL
VK	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Mucosa	NULL
specific	NULL
lym-phocytes	NULL
in	NULL
the	NULL
human	NULL
conjunctiva	NULL
,	NULL
corneoscleral	NULL
limbus	NULL
and	NULL
lacrimal	NULL
gland	NULL
.	NULL

Curr	NULL
Eye	NULL
Res	NULL
1994	NULL
;	NULL
13:87-93	NULL
.	NULL

Gregerson	NULL
DS	NULL
,	NULL
Obstrisch	NULL
WF	NULL
,	NULL
Donoso	NULL
LA	NULL
.	NULL

Oral	NULL
tolerance	NULL
in	NULL
experimental	NULL
autoimmune	NULL
uveoretinitis	NULL
:	NULL
distinct	NULL
mechanisms	NULL
of	NULL
resistance	NULL
are	NULL
induced	NULL
by	NULL
low	NULL
zone	NULL
versus	NULL
high	NULL
zone	NULL
feeding	NULL
protocols	NULL
.	NULL

J	NULL
Immunol	NULL
1993	NULL
;	NULL
151:5751-61	NULL
.	NULL

Kreutzer	NULL
B	NULL
,	NULL
Laliotou	NULL
B	NULL
,	NULL
Cheng	NULL
Y	NULL
,	NULL
e	NULL
al	NULL
.	NULL

Nasal	NULL
antigen	NULL
administration	NULL
of	NULL
retinal	NULL
antigens	NULL
maintains	NULL
immuosup-pression	NULL
of	NULL
uveoretinitis	NULL
in	NULL
cyclosporin	NULL
A	NULL
treated	NULL
Lewis	NULL
rats	NULL
:	NULL
future	NULL
treatment	NULL
of	NULL
endogenous	NULL
posterior	NULL
uveoretinitis	NULL
.	NULL

Eye	NULL
1997	NULL
;	NULL
11:445-5	NULL
.	NULL

Thurau	NULL
SR	NULL
,	NULL
Chan	NULL
CC	NULL
,	NULL
Nussenblatt	NULL
RB	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Oral	NULL
tolerance	NULL
in	NULL
a	NULL
murine	NULL
model	NULL
of	NULL
relapsing	NULL
experimental	NULL
autoimmune	NULL
uveoretinitis	NULL
(	NULL
EAU	NULL
)	NULL
:	NULL
induction	NULL
of	NULL
protective	NULL
tolerance	NULL
in	NULL
primed	NULL
animals	NULL
.	NULL

Clin	NULL
Exp	NULL
Immunol	NULL
1997	NULL
;	NULL
109:370-452	NULL
.	NULL

Dick	NULL
AD	NULL
,	NULL
Kreutzer	NULL
B	NULL
,	NULL
Laliotou	NULL
B	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Effects	NULL
of	NULL
mycophe-nolate	NULL
mofetil	NULL
on	NULL
nasal	NULL
mucosal	NULL
tolerance	NULL
induction	NULL
.	NULL

Invest	NULL
Ophthalmol	NULL
Vis	NULL
Sci	NULL
1998	NULL
;	NULL
39:835-40	NULL
.	NULL

Nussenblatt	NULL
RB	NULL
,	NULL
Gery	NULL
I	NULL
,	NULL
Weiner	NULL
HL	NULL
,	NULL
ef	NULL
al	NULL
.	NULL

Treatment	NULL
of	NULL
uveitis	NULL
by	NULL
oral	NULL
administration	NULL
of	NULL
retinal	NULL
antigens	NULL
:	NULL
results	NULL
of	NULL
a	NULL
phase	NULL
I/II	NULL
randomized	NULL
masked	NULL
trial	NULL
.	NULL

Am	NULL
J	NULL
Ophthalmol	NULL
1997	NULL
;	NULL
23:583-92	NULL
.	NULL

Liu	NULL
GY	NULL
,	NULL
Wraith	NULL
DC	NULL
.	NULL

Affinity	NULL
for	NULL
class	NULL
II	NULL
MHC	NULL
determines	NULL
the	NULL
extent	NULL
to	NULL
which	NULL
soluble	NULL
peptides	NULL
tolerize	NULL
autoreactive	NULL
T	NULL
cells	NULL
in	NULL
naive	NULL
and	NULL
primed	NULL
adult	NULL
micc-implications	NULL
for	NULL
autoimmunity	NULL
.	NULL

Int	NULL
Immunol	NULL
1995	NULL
;	NULL
7:1255-63	NULL
.	NULL

Anderton	NULL
SM	NULL
,	NULL
Wraith	NULL
DC	NULL
.	NULL

Hierarchy	NULL
in	NULL
the	NULL
ability	NULL
of	NULL
T	NULL
cell	NULL
epitopes	NULL
to	NULL
induce	NULL
peripheral	NULL
tolerance	NULL
to	NULL
antigens	NULL
from	NULL
myclin	NULL
.	NULL

Eur	NULL
J	NULL
Immunol	NULL
1251-61	NULL
.	NULL

Liblau	NULL
R	NULL
,	NULL
Tisch	NULL
R	NULL
,	NULL
Bercovici	NULL
N	NULL
;	NULL
et	NULL
al	NULL
.	NULL

Systemic	NULL
antigen	NULL
in	NULL
the	NULL
treatment	NULL
of	NULL
T	NULL
cell	NULL
mediated	NULL
autoimmune	NULL
discase	NULL
.	NULL

Immunol	NULL
Today	NULL
1997	NULL
;	NULL
18:599-604	NULL
.	NULL

Hoyne	NULL
GF	NULL
,	NULL
Askonas	NULL
BA	NULL
,	NULL
Hetzel	NULL
C	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Regulation	NULL
of	NULL
house	NULL
dust	NULL
mite	NULL
responses	NULL
by	NULL
intranasally	NULL
administered	NULL
peptide	NULL
:	NULL
transient	NULL
activation	NULL
of	NULL
CD4+	NULL
T	NULL
cells	NULL
precedes	NULL
the	NULL
development	NULL
of	NULL
tolerance	NULL
in	NULL
vivo	NULL
.	NULL

Int	NULL
Immunol	NULL
1996	NULL
;	NULL
8:335-42	NULL
.	NULL

Laliotou	NULL
B	NULL
,	NULL
Duncan	NULL
L	NULL
,	NULL
Dick	NULL
AD	NULL
.	NULL

Intranasal	NULL
administration	NULL
of	NULL
retinal	NULL
antigens	NULL
induces	NULL
transient	NULL
T	NULL
cell	NULL
activation	NULL
and	NULL
apoptosis	NULL
within	NULL
drainage	NULL
lymph	NULL
node	NULL
but	NULL
not	NULL
spleen	NULL
.	NULL

J	NULL
Autoimmun	NULL
1999	NULL
;	NULL
12:145-55	NULL
.	NULL

Burkhart	NULL
C	NULL
,	NULL
Liu	NULL
GY	NULL
Anderton	NULL
SM	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Peptide-induced	NULL
T	NULL
cell	NULL
regulation	NULL
of	NULL
experimental	NULL
autoimmune	NULL
encephalomyelitis	NULL
:	NULL
a	NULL
role	NULL
for	NULL
IL-10	NULL
.	NULL

Int	NULL
Immunol	NULL
1999	NULL
;	NULL
11	NULL
:	NULL
1625-34	NULL
.	NULL

Laliotou	NULL
B	NULL
,	NULL
Dick	NULL
AD	NULL
.	NULL

Modulating	NULL
phenotype	NULL
and	NULL
cytokine	NULL
production	NULL
of	NULL
leukocyte	NULL
retinal	NULL
infiltrate	NULL
in	NULL
experimental	NULL
autoimmune	NULL
uveoretintis	NULL
following	NULL
intranasal	NULL
tolerance	NULL
induction	NULL
with	NULL
retinal	NULL
antigens	NULL
.	NULL

Br	NULL
J	NULL
Ophthalmol	NULL
1999	NULL
;	NULL
83	NULL
:	NULL
478-85	NULL
.	NULL

Wolvers	NULL
DA	NULL
,	NULL
Coenen-de	NULL
Roo	NULL
CJ	NULL
,	NULL
Mebius	NULL
RE	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Intranasally	NULL
induced	NULL
immunological	NULL
tolerance	NULL
is	NULL
determined	NULL
by	NULL
characteristics	NULL
of	NULL
the	NULL
draining	NULL
lymph	NULL
nodes	NULL
:	NULL
studies	NULL
with	NULL
OVA	NULL
and	NULL
human	NULL
cartilage	NULL
gp-39	NULL
.	NULL

J	NULL
Immunol	NULL
1999	NULL
;	NULL
162	NULL
;	NULL
1994-8.	NULL
www	NULL
.	NULL

bjophthalmol	NULL
.	NULL

com	NULL
21	NULL
22	NULL
23	NULL
24	NULL
25	NULL
26	NULL
27	NULL
28	NULL
29	NULL
30	NULL
31	NULL
32	NULL
33	NULL
34	NULL
35	NULL
36	NULL
37	NULL
38	NULL
39	NULL
44	NULL
o	NULL
Dick	NULL
,	NULL
Sharma	NULL
,	NULL
Liversidge	NULL
Banchereau	NULL
J	NULL
,	NULL
Briere	NULL
F	NULL
,	NULL
Caux	NULL
C	NULL
,	NULL
e	NULL
al	NULL
.	NULL

Immunobiology	NULL
of	NULL
dendritic	NULL
cells	NULL
.	NULL

Annu	NULL
Rev	NULL
Immunol	NULL
2000	NULL
;	NULL
18:767-811	NULL
.	NULL

Holt	NULL
PG	NULL
,	NULL
Stumbles	NULL
PA	NULL
,	NULL
McWilliam	NULL
AS	NULL
.	NULL

Functional	NULL
studies	NULL
on	NULL
dendritic	NULL
cells	NULL
in	NULL
the	NULL
respiratory	NULL
tract	NULL
and	NULL
related	NULL
mucosal	NULL
tissue	NULL
.	NULL

7	NULL
Leuk	NULL
Biol	NULL
1999	NULL
;	NULL
66:272-5	NULL
.	NULL

Holt	NULL
G	NULL
,	NULL
Schon-Hegrad	NULL
MA	NULL
,	NULL
Oliver	NULL
J	NULL
,	NULL
et	NULL
al	NULL
.	NULL

A	NULL
contiguous	NULL
network	NULL
of	NULL
dendritic	NULL
antigen	NULL
presenting	NULL
cells	NULL
within	NULL
the	NULL
respiratory	NULL
epithelium	NULL
.	NULL

Int	NULL
Arch	NULL
Allergy	NULL
Appl	NULL
Immunol	NULL
1990	NULL
;	NULL
91:155-9	NULL
.	NULL

Stumbles	NULL
PA	NULL
,	NULL
Thomas	NULL
JA	NULL
,	NULL
Pimm	NULL
CL	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Resting	NULL
respiratory	NULL
tract	NULL
dendritic	NULL
cells	NULL
preferentially	NULL
stimulate	NULL
T	NULL
helper	NULL
cell	NULL
type	NULL
2	NULL
(	NULL
Th2	NULL
)	NULL
responses	NULL
and	NULL
require	NULL
obligatory	NULL
cytokine	NULL
signals	NULL
for	NULL
induction	NULL
of	NULL
Thl	NULL
immunity	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
1998	NULL
;	NULL
188:2019-31	NULL
.	NULL

Masten	NULL
BJ	NULL
,	NULL
Lipscomb	NULL
ME	NULL
.	NULL

Comparison	NULL
of	NULL
lung	NULL
dendritic	NULL
cells	NULL
and	NULL
B	NULL
cells	NULL
in	NULL
stimulating	NULL
naive	NULL
antigen-specific	NULL
T	NULL
cells	NULL
.	NULL

7	NULL
Immunol	NULL
1999	NULL
;	NULL
162:1310-18	NULL
.	NULL

Koch	NULL
F	NULL
,	NULL
Stanzel	NULL
U	NULL
,	NULL
Jennewein	NULL
P	NULL
,	NULL
et	NULL
al	NULL
.	NULL

High	NULL
level	NULL
IL-12	NULL
production	NULL
by	NULL
murine	NULL
dendritic	NULL
cells	NULL
:	NULL
upregulation	NULL
via	NULL
MHC	NULL
class	NULL
II	NULL
and	NULL
CD40	NULL
molecules	NULL
and	NULL
downregulation	NULL
by	NULL
IL-4	NULL
and	NULL
IL-10	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
1996	NULL
;	NULL
184:741-9	NULL
.	NULL

Jiang	NULL
HR	NULL
,	NULL
Taylor	NULL
N	NULL
,	NULL
Duncan	NULL
L	NULL
,	NULL
et	NULL
al	NULL
Total	NULL
dose	NULL
and	NULL
frequency	NULL
of	NULL
administration	NULL
critically	NULL
determine	NULL
the	NULL
success	NULL
of	NULL
nasal	NULL
tolerance	NULL
induction	NULL
.	NULL

Br	NULL
J	NULL
Ophthalmol	NULL
(	NULL
in	NULL
press	NULL
)	NULL
.	NULL

Laliotou	NULL
B	NULL
,	NULL
Liversidge	NULL
J	NULL
,	NULL
Forrester	NULL
JV	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Interphotorcccp—	NULL
tor	NULL
retinoid	NULL
binding	NULL
protein	NULL
is	NULL
a	NULL
potent	NULL
tolerogen	NULL
in	NULL
Lewis	NULL
rat	NULL
:	NULL
suppression	NULL
of	NULL
experimental	NULL
autoimmune	NULL
uveoretinitis	NULL
is	NULL
retinal	NULL
antigen	NULL
specific	NULL
.	NULL

Br	NULL
J	NULL
Ophthalmol	NULL
1997	NULL
;	NULL
81:1-7	NULL
.	NULL

Liversidge	NULL
J	NULL
,	NULL
Dawson	NULL
R	NULL
,	NULL
Dick	NULL
AD	NULL
,	NULL
et	NULL
al	NULL
Uveitogenic	NULL
epitopes	NULL
of	NULL
retinal	NULL
S-antigen	NULL
are	NULL
generated	NULL
in	NULL
vivo	NULL
via	NULL
an	NULL
alternative	NULL
antigen	NULL
presenting	NULL
pathway	NULL
.	NULL

Immunology	NULL
1998	NULL
;	NULL
94:503-13	NULL
.	NULL

Wurster	NULL
Al	NULL
,	NULL
Tanaka	NULL
T	NULL
,	NULL
Grusby	NULL
MJ	NULL
.	NULL

The	NULL
biology	NULL
of	NULL
Stat4	NULL
and	NULL
Stat6	NULL
.	NULL

Oncogene	NULL
2000	NULL
;	NULL
19:2577-84	NULL
.	NULL

Metzler	NULL
B	NULL
,	NULL
Anderton	NULL
SM	NULL
,	NULL
Manickasingham	NULL
SP	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Kinct-ics	NULL
of	NULL
peptide	NULL
uptake	NULL
and	NULL
tissue	NULL
redistribution	NULL
following	NULL
a	NULL
single	NULL
intranasal	NULL
dose	NULL
of	NULL
peptide	NULL
.	NULL

Immunol	NULL
Invest	NULL
2000	NULL
;	NULL
29	NULL
:	NULL
61-70	NULL
.	NULL

Shi	NULL
FD	NULL
,	NULL
Li	NULL
H	NULL
,	NULL
Wang	NULL
H	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Mechanisms	NULL
of	NULL
nasal	NULL
tolerance	NULL
induction	NULL
in	NULL
experimental	NULL
autoimmune	NULL
myasthenia	NULL
gravis	NULL
:	NULL
identification	NULL
of	NULL
regulatory	NULL
cells	NULL
.	NULL

J	NULL
Immunol	NULL
1999	NULL
;	NULL
162	NULL
;	NULL
5757-63	NULL
.	NULL

Chen	NULL
Y	NULL
,	NULL
Inobe	NULL
JI	NULL
,	NULL
Kuchroo	NULL
VK	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Oral	NULL
tolerance	NULL
in	NULL
myelin	NULL
basic	NULL
protein	NULL
T	NULL
cell	NULL
receptor	NULL
transgenic	NULL
mice	NULL
:	NULL
suppression	NULL
of	NULL
autoimmune	NULL
encephalomyclitis	NULL
and	NULL
dose-dependent	NULL
induction	NULL
of	NULL
regulatory	NULL
cells	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sct	NULL
(	NULL
USA	NULL
)	NULL
1996	NULL
;	NULL
93:388-91	NULL
.	NULL

Tsitoura	NULL
DC	NULL
,	NULL
DeKruyff	NULL
RH	NULL
,	NULL
Lamb	NULL
JR	NULL
,	NULL
&	NULL
al	NULL
.	NULL

Intranasal	NULL
exposure	NULL
to	NULL
protein	NULL
antigen	NULL
induces	NULL
immunological	NULL
tolerance	NULL
mediated	NULL
by	NULL
functionally	NULL
disabled	NULL
CD4+	NULL
T	NULL
cells	NULL
.	NULL

7	NULL
Immunol	NULL
1999	NULL
;	NULL
163:2592-600	NULL
.	NULL

Bacon	NULL
CM	NULL
,	NULL
Petricoin	NULL
EF	NULL
,	NULL
Ortaldo	NULL
JR	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Interleukin	NULL
12	NULL
induces	NULL
tyrosine	NULL
phosphorylation	NULL
and	NULL
activation	NULL
of	NULL
STAT4	NULL
in	NULL
human	NULL
lymphocytes	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
1995	NULL
;	NULL
92	NULL
;	NULL
7307-11	NULL
.	NULL

Jacobson	NULL
NG	NULL
,	NULL
Szabo	NULL
SJ	NULL
,	NULL
Weber-Nordt	NULL
RM	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Interleukin	NULL
12	NULL
signaling	NULL
in	NULL
T	NULL
helper	NULL
1	NULL
(	NULL
Th1l	NULL
)	NULL
cells	NULL
involves	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
signal	NULL
transducer	NULL
and	NULL
activator	NULL
of	NULL
transcription	NULL
(	NULL
Stat	NULL
)	NULL
3	NULL
and	NULL
Stat4	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
1995	NULL
;	NULL
181:1755-62	NULL
.	NULL

Jackson	NULL
SK	NULL
,	NULL
DeLoose	NULL
A	NULL
,	NULL
Gilbert	NULL
KM	NULL
.	NULL

Induction	NULL
of	NULL
anergy	NULL
in	NULL
Thl1	NULL
cells	NULL
associated	NULL
with	NULL
increased	NULL
levels	NULL
of	NULL
cyclin-dependent	NULL
kinase	NULL
inhibitors	NULL
p21Cipl	NULL
and	NULL
p27Kipl	NULL
.	NULL

J	NULL
Immunol	NULL
2001	NULL
;	NULL
166:952-8	NULL
.	NULL

Marth	NULL
T	NULL
,	NULL
Zeitz	NULL
M	NULL
,	NULL
Ludviksson	NULL
BR	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Extinction	NULL
of	NULL
IL-12	NULL
signaling	NULL
promotes	NULL
Fas-mediated	NULL
apoptosis	NULL
of	NULL
antigen-specific	NULL
T	NULL
cells	NULL
.	NULL

J	NULL
Immunol	NULL
1999	NULL
;	NULL
162:7233-41	NULL
.	NULL

Pardoux	NULL
C	NULL
,	NULL
Ma	NULL
X	NULL
,	NULL
Gobert	NULL
8	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Down	NULL
regulation	NULL
of	NULL
Interleukin	NULL
12	NULL
(	NULL
IL-12	NULL
)	NULL
responsiveness	NULL
in	NULL
human	NULL
T	NULL
cells	NULL
by	NULL
transforming	NULL
growth	NULL
factor-B	NULL
:	NULL
relationship	NULL
with	NULL
IL-12	NULL
signalling	NULL
.	NULL

Blood	NULL
1448-55	NULL
.	NULL

Wolvers	NULL
DA	NULL
,	NULL
van	NULL
der	NULL
Camen	NULL
MJ	NULL
,	NULL
Kraal	NULL
G.	NULL
Mucosal	NULL
tolerance	NULL
is	NULL
associated	NULL
with	NULL
,	NULL
but	NULL
independent	NULL
of	NULL
,	NULL
up-regulation	NULL
Th2	NULL
responses	NULL
.	NULL

Immunology	NULL
1997	NULL
;	NULL
92:328-33	NULL
.	NULL

